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Abstract 
 
 
In the environment in which palatable and highly caloric foods are readily 
available, eating behavior is oftentimes not dictated by the necessity to replenish 
lacking energy, but rather by the pleasure of consumption. Centrally acting 
oxytocin (OT) is known to promote termination of feeding to protect internal 
milieu by preventing excessive stomach distension, hyperosmolality and 
ingestion of toxins. Initial evidence suggests that another possible role for OT in 
mechanisms governing food intake is to reduce consumption of select palatable 
tastants. This thesis explores the question whether OT is as an appetite 
suppressant that reduces feeding reward.  
The first set of experiments addresses whether OT affects intake of (a) all 
carbohydrates, (b) only sweet carbohydrates or (c) sweet non-carbohydrate 
saccharin in mice. In those studies, generalized injection of a blood brain barrier 
penetrant OT receptor antagonist, L-368,899, significantly increased the intake of 
sweet (sucrose, glucose, fructose, polycose) and non-sweet (cornstarch) 
carbohydrates and promoted a trend approaching significance in saccharin 
consumption. Consumption of carbohydrate-enriched foods led to an increase in 
OT mRNA levels in the hypothalamus. 
The second set of studies identifies the nucleus accumbens core (AcbC), a key 
component of the reward system, as a site that mediates anorexigenic effects of 
OT. Rats injected with OT directly in the AcbC showed a decreased intake of 
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sucrose and saccharin solutions as well as of standard chow. This treatment did 
not cause taste aversion, hence the outcome was not due to sickness/malaise. 
The effects of AcbC OT on feeding could be observed only in animals offered a 
meal in a non-social environment. Once a social setting (devoid of direct 
antagonistic interactions between individuals) of a meal was introduced, AcbC 
OT failed to reduce feeding. AcbC levels of OT receptor transcript were affected 
by exposure to palatable food as well as by food deprivation. 
The third and final set of studies shows that aberrant integrity of neuronal 
circuitry within the neuroendocrine and reward systems due to genetic deletion 
of connexin 36 (Cx36) gap junctions leads to dysregulation of the OT system’s 
functioning in the Cx36 KO mouse. This dysregulation is associated with 
hypersensitivity to aversive properties of foods, reduced interest in feeding for 
reward (palatable carbohydrates and saccharin) and abnormal ingestion of 
energy.  
Overall, the findings suggest that OT diminishes feeding for reward, particularly 
the intake of palatable carbohydrates and saccharin, by acting – at least in part – 
via the reward system. OT appears to be part of central mechanisms that cross-
link homeostasis-driven and palatability-related (i.e., flavor- and macronutrient-
specific) termination of consumption.  
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Chapter 1 
 
Introduction and Aims 
 
 
Obesity is a public health issue worldwide and overeating greatly contributes to 
its prevalence. It is therefore essential to understand the mechanisms that 
regulate eating behavior and to identify new therapeutic targets. While the 
disruption of the "hunger-satiety" signaling oftentimes leads to excessive body 
weight [1], it is apparent that laboratory animals and humans oftentimes eat for 
reasons other than hunger.  In the obesogenic environment, the usual reason to 
initiate and maintain food intake is a pleasant taste of food, i.e., feeding reward. 
When feeding reward comes into play, satiety is delayed. Therefore, the current 
research effort to limit excessive food intake underlying obesity is directed 
towards identifying mechanisms and molecules that promote early satiety in the 
context of eating for pleasure. Initial evidence suggests that oxytocin (OT) may 
act as a feeding inhibitor that cross-links satiety and reward. The exact nature of 
the functional relationship between OT and the regulation of palatability-driven 
appetite remains unclear.  Thus, in this thesis I explore whether OT is as an 
appetite suppressant that reduces feeding reward.  
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1.1. Oxytocin and receptors 
1.1.1 Oxytocin 
The neuropeptide hormone oxytocin is a nonapeptide (Cys–Tyr–Ile–Gln–Asn–
Cys–Pro–Leu–GlyNH2) (Figure. 1.1) with a sulfur bridge between the two 
cysteines. OT was extracted from the mammalian pituitary in 1950, and it 
became the first sequenced and structurally-defined neuropeptide [2]. This 
neuropeptide is evolutionarily conserved across phyla and has been detected in 
most vertebrate and several invertebrate species [3-6]. Some variability of the 
OT amino acid sequences has been shown in vertebrates, for example, in 
cartilaginous fishes (isotocin [S4,I8]-oxytocin)  and in birds [7], reptiles and 
amphibians (mesotocin [I8]-oxytocin) [8-10]. There is also some variability in the 
OT-like molecular structure in invertebrates. For example, inotocin has been 
identified in ants [11], whereas some insects, such as Drosophila melanogaster, 
lack the OT molecule whatsoever [5]. Acher et al. date the precursor of OT gene 
at 500 million years [12]. The fact that OT is highly conserved among the plethora 
of phyla and species strongly indicates that it plays a crucial role relevant to the 
basic functioning of the organism. The proposed function of OT in the control of 
energy intake and nutrient preference/selectivity further explored in this thesis, 
fits in the notion of the critical place of OT in regulatory mechanisms that are 
most essential in the survival of the organism: energy and nutrient homeostasis 
ensure the proper biochemical environment for cellular and system physiological 
responses to occur. Though it is not the topic of this thesis, it should be 
mentioned that OT’s role in such elementary functions is not limited to food 
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intake, but it also includes e.g. reproduction and associative learning (from 
Caenorhabditis elegans to Eisenia foetida to humans [12-15]).  
 
Figure 1.1: A phylogenetic tree including the structure of OT and OT-related peptides 
and their receptors. Figure adapted from Koehbach J  et al 2013 [16].   
 
The OT gene is localized in humans in chromosomal loci 20p13 [17]. After being 
transcribed, translated and spliced, an inactive gene product precursor protein 
that contains the signal peptide (at the N-terminus), OT, and neurophysin (at the 
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C-terminus), is formed. The full structure of the OT precursor protein is shown in 
Figure 1.2. The OT prepropeptide is package into the granules of the Golgi 
apparatus. The prepropeptide undergoes cleavage and modifications during the 
post-Golgi transport phase to axon terminals [18-20]. 
 
Figure 1.2: Domain organization of preprooxytocin. Figure adapted from from Gimpl G 
et al. 2001 [20] 
 
In the central nervous system (CNS), OT is synthesized mainly in the supraoptic 
(SON) and paraventricular (PVN) nuclei of the hypothalamus as well as in 
hypothalamic magnocellular accessory neurons located between the PVN and 
SON [21]. Both the PVN and SON contain OT magnocellular populations, whereas 
the PVN hosts also parvocellular OT neurons. Magnocellular neurons release OT 
primarily to the general circulation via the posterior pituitary. On the other hand, 
parvocellular OT neurons send their projections not only to the neurohypophysis, 
but also to a variety of central sites. Importantly, many of the brain areas 
targeted by the OT system are involved in the regulation of food intake. Those 
sites include, for example, the components of the reward system (the nucleus 
accumbens and ventral tegmental area) as well as the energy balance-related 
CNS regions (for example, the nucleus of the solitary tract and the dorsal motor 
nucleus of the vagus)  (Figure.1.3) [22, 23]. Therefore, CNS-derived OT controls 
feeding as well as other physiological and behavioral outcomes via its receptors 
scattered throughout the brain as well as in peripheral organs [19, 24-27]. 
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Figure 1.3: Parvocellular neurons of the PVN project to a variety of brain areas where 
OTr is expressed. Magnocellular neurons of the PVN (red) and SON (black) project to the 
posterior pituitary to release OT to the general circulation. It should be noted that the 
distribution of the OTr is very vast and it incorporates sites that govern a wide number 
of processes, such as reward (VTA and Acb), stress (AMY), learning and memory 
(hippocampus), maternal behavior (MPOA/BNST and OB) and periphery-CNS relay 
mechanisms (brain stem). Figure adapted from Rutherford HJ et al. 2011 [28]. (PVN: 
Paraventricular nucleus of the hypothalamus, SON: Supraoptic nucleus, VTA: Ventral 
tegmental area, Acb : Nucleus accumbens, AMY: Amygdala, MPOA: Medial Preoptic Area, 
BNST: Bed nucleus of the stria terminalis OB: Olfactory bulb).  
 
 
1.1.2 Oxytocin receptor 
The oxytocin receptor (OTr) gene, containing three introns and four exons, is 
localized in humans on chromosomal loci 3p25 and 3p26.2 [29, 30], and its 
transcription is controlled by several transcription factors, including 
inflammatory and immune mediators, cAMP, estrogen and steroids [31-33].  
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Figure 1.4: Schematic representation of the OTr structure with its seven transmembrane 
domains and the interaction site with the OT molecule. Figure adapted from Zingg HH et 
al. 2003 [34]. 
 
The OTr belongs to the superfamily of the rhodopsin-type (class I) G protein-
coupled receptors (GPCR) having seven transmembrane domains and the α helix 
and it is highly conserved in mammalian genomes Figure 1.4.  In Class I GPCR 
family, the amino acid aspartic acid in domain 2 is important in the process of 
receptor activation. [35]. The native OT molecule shows the superior affinity for 
the OTr. It should be mentioned, however, that also the endogenous vasopressin 
(VP) can bind the OTr, but the affinity for of the OTr for OT is 10 times higher 
than for VP, and the concentration of VP necessary to bind the OTr - 100 times 
higher than OT [36, 37].  
The OTr binding site for its ligand is formed by extracellular loops 2 and 4 and 
part of the transmembrane domains 2 and 4 (Figure 1.4). In fact, the binding of 
an agonist peptide to transmembrane domains of the OTr on the cell surface 
changes receptor’s conformation and activates the hydrolysis of GDP to GTP in 
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the G protein, separating it into the α and β subunits. This separation followed by 
hydrolysis by phosphorylase C-β of phosphatidyl-inositol-4-5-diphosphate (PIP2) 
into inositol triphosphate (IP3) and 1,2-diacylglycerol (DAG). DAG allows 
activation of protein kinase C and IP3, release of Ca2+ and initiation of cellular 
responses [38-41], such as cell excitability processes, transmitter release and/or 
synthesis of proteins [42] (Figure 1.5). 
 
Figure 1.5: Activation of OTr signaling pathway by OT. G protein, α and β subunits 
(Gαβ) C-β of phosphatidyl-inositol-4-5-diphosphate (PIP2), inositol triphosphate (IP3) 
and 1,2-diacylglycerol (DAG), Guanosine-5'-triphosphate (GTP), guanosine diphosphate 
(GDP), Protein kinase C (PKC).  
 
The endogenous OT molecule has a relatively short half-life and a very limited 
ability to cross the blood-brain barrier (BBB) [43]. These two issues are 
considered to be significant obstacles in using OT in various pharmacological 
application scenarios in which the native ligand is to act the CNS receptors. 
Therefore, substantial research effort has been directed towards developing 
synthetic ligands of the OTr. The past two decades of studies have produced the 
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development of OTr agonists and antagonists characterized by improved BBB 
permeability parameters and/or longer half-life (an overview of currently 
available ligands is presented in Table 1.1).   
Table 1.1: Oxytocin receptor ligands 
Agonist Antagonist 
Peptide Non-peptide Peptide Non-peptide 
Carbetocin WAY-267,464  Atosiban L-368,899 
Demoxytocin 
  
Barusiban L-371,257 
Lipo-oxytocin-1 
    
L-372,662 
Merotocin 
    
SSR-126,768 
Oxytocin 
    
Epelsiban 
      
Retosiban 
      
WAY-162,720 
 
L-368,899 is one of the most frequently used OTr antagonists in research [44,45] 
(Figure 1.6).  L-368,899 is a unique ligand that rapidly penetrates into the brain 
due to its capacity to cross the BBB [45,46] with accumulation in areas of 
the limbic system [46].  It has been employed in studies on, among others, central 
regulation of food intake or sexual activity [47,48]. 
 
 
Figure 1 6: Chemical structure of [14C]L-368,899  
 
Approximately 80% of OT receptors are present in the CNS [49,50]. The 
distribution of this receptor mirrors the involvement of OT in numerous 
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physiological and behavioral processes, from food intake to stress to maternal 
behavior (see Section 1.2 for details on key functions of OT). OTr has been found 
in specific sites involved in the regulation of food intake, such as the nucleus 
accumbens (Acb), the ventral tegmental area (VTA), the hypothalamus and the 
brainstem [51-54]. The OTr mRNA has been also detected in the anterior 
olfactory nucleus, ventral pallidum, limbic system (bed nucleus of the stria 
terminalis, central amygdaloid nucleus, ventral subiculum), and hypothalamus 
[50, 55][56], with no major differences in distribution between males and 
females [49] (Figure 1.3; Table 1.2). 
 
Table 1.2: The distribution of the OTr in the rats CNS. Adapted from Gimpl G et al. [20]. 
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1.2. Main behavioral and physiological effects of oxytocin 
The vast peripheral and central distribution of the OTr underlies multiple 
functions played by OT, including the regulation of maternal, sexual, aggressive, 
affiliative, grooming and feeding behavior and physiology [57].  
OT’s roles in parturition and in the milk ejection reflex have been most avidly 
studied. OT induces contractions of the smooth muscle of the uterus leading to 
parturition. Expression of OTr mRNA and density of this receptor on the surface 
of the myometrium increase in the presence of estradiol [58][59,60], which 
precedes the active phase of the birth process. Following parturition, OT levels 
remain high and OT starts playing a crucial function in facilitating milk ejection 
[61]. Stimulation of tactile receptors by suckling, generates impulses transmitted 
from the nipple to the spinal cord and then to OT neurons in the hypothalamus 
[57,62].   
Not only does OT ensure the proper physiological responses during and after 
parturition, but it also facilitates the development of the appropriate repertoire 
of a mother’s social responses to the young [38-40,63,64]. It is particularly 
important in initiating maternal behavior [41]. Noteworthy, human studies show 
also the link between OT and both maternal and paternal responses to a 
newborn [65]. Furthermore, epigenetics (genomic imprinting) may control this 
hormonal and behavioral responsiveness to the offspring via the paternal and 
maternal genome [66,67]. 
The social bonding effects of OT extend well beyond parent-child relations. In 
humans, OT mediates the benefits of positive social interaction and emotions 
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stemming from non-family bonds. OT is released in the brain and into the 
periphery by stimuli such as touch, warmth, etc. Consequently, OT may facilitate 
physiological and behavioral effects induced by social interaction [68].  
Administration of OT has been reported to increase feelings of affiliation to one’s 
parents, decrease stress and anxiety in both men and women and promote 
effects such as the reduction in blood pressure and cortisol levels  [69-71]. 
Intranasal administration of OT causes increased subjective feelings of 
attachment, generosity, sensitivity to emotion and maintenance of trust [69,72-
74]. Indeed, in game-scenario experiments, intranasal OT prevented the loss of 
trust in an opponent even after the trust has been breached by this opponent 
before [75]. OT also improves the ability to infer the mental state of others from 
physical cues (facial expressions) [76,77]. Recently, the beneficial clinical effects 
of OT treatment on positive social interactions in autism (disorder characterized 
by impaired social interactions and communication) have been reported [78]. In 
laboratory animals, central administration of OT agonists enhances social 
recognition, memory for peers, the development of partner preference, and 
partner bonding [79]. Importantly, centrally administered OT promotes 
termination of food intake (Sections 1.3 and 1.4 describe the findings in detail) 
[80]. Experiments in rodents have shown that OT inhibits food intake through 
receptors localized throughout the brain. Indeed, central OT administration 
reduces food intake and prolongs latency to eat [81]. In addition, anorexia-
inducing agents such as lithium chloride (LiCl) stimulate OT secretion into the 
periphery and in the CNS leading to the termination of food intake [82,83]. OT 
knockout (KO) mice show increased preference for palatable (sweet) 
carbohydrates [47]. 
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1.3 Mechanisms controlling food intake: focus on the role 
of oxytocin 
Proper energy balance is critical for survival of the organism. Maintenance of 
energy homeostasis depends on a variety of mechanisms, including those that 
regulate food consumption. Importantly, food intake should not be viewed in a 
simplistic manner as a mere means of acquiring calories, but rather a set of 
complex physiological and (consequently) behavioral processes. They allow the 
animal to obtain energy and diverse nutrients, without jeopardizing internal 
milieu (e.g., by inadvertently introducing toxins or an excessive osmotic load). 
Therefore, the complexity of appetite regulating mechanisms stems from the 
ever-present need to have consummatory behavior adapt to constant changes in 
the internal (such as neurohormonal, osmotic, chemoreceptor-, 
mechanoreceptor- and nutrient-derived signals) and external environment (light-
dark cycle; social context, etc.). While this aspect of food intake control – for the 
purpose of this thesis dubbed “homeostatic” – is a key component affecting 
consumption, one should not forget that appetite is shaped by another critical 
factor, i.e., feeding reward. [84]. In fact, mechanisms promoting ingestive 
behavior driven by pleasant taste have been suggested to play such a significant 
role in modifying one’s consumption profile that, under many circumstances, 
they may outweigh homeostatic controls of feeding [85].  
Noteworthy, OT has been speculated to affect both homeostatic and reward-
related ingestive behavior. The vast majority of evidence points to the 
brainstem-hypothalamus OT reciprocal pathways as mediators of homeostatic 
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aspects of food intake regulation, including responsiveness to changes in plasma 
osmolality, excessive distension of the stomach and avoidance of foods whose 
ingestion might cause sickness/malaise. Much less is known about the 
involvement of OT in feeding for pleasure, although evidence gathered to date 
suggests that OT diminishes appetite for sweet and/or carbohydrate tastants – at 
least partially – via the ventral tegmental area (VTA). Sections 1.3.1 and 1.3.2 
provide more theoretical background on the involvement of OT in specific 
mechanisms affecting ingestive behavior and physiological processes related to 
feeding. 
1.3.1. Oxytocin and homeostatic control of food intake 
1.3.1.1. Oxytocin and satiety-driven termination of food intake 
Early on it became apparent that the hypothalamus is a key central region 
responsible for the regulation of appetite. One of the pioneering studies showed 
that deletion of the PVN in rodents produces excessive food consumption and 
result in the obese phenotype [86]. Subsequent experiments indicated that the 
PVN is not the sole player in feeding regulatory mechanisms and a host of other 
neuroanatomical substrates of the hypothalamus were added to the list of – 
using the nomenclature of those early reports – “satiety/hunger centers”. Those 
sites include the SON, ventromedial hypothalamus (VMH), dorsomedial 
hypothalamic nucleus (DMH), lateral hypothalamus (LHA) and arcuate nucleus 
(ARC)[87,88]. Among those, the ARC has been shown to be directly affected by 
the presence of adipose-derived hormone, leptin, in the general circulation [89] 
[90]. The question arose as to how else (other than through the direct input into 
the ARC) the hypothalamic areas receive relevant signals that modify 
36 
 
neuroendocrine responses accompanying changes in ingestive behavior 
associated with hunger and satiety. It led to identification of the dorsal vagal 
complex (DVC), the nucleus of the solitary tract (NTS), dorsal motor nucleus of 
the vagus (DMNV) and area postrema (AP) as a “relay” region that integrates 
neural (mainly, vagally mediated), hormonal (e.g. cholecystokinin) and 
biochemical/chemical (plasma ion/toxin profile) input related to consummatory 
activity.  Data strongly suggest neuroanatomical and functional reciprocity in the 
appetite-related functioning of the brainstem-hypothalamic circuit (and that 
includes the OT neuronal populations which both receive brainstem-derived 
innervation and project toward the DVC [91]. Figure 1.9 shows a schematic 
representation of an example of feeding-related neuroendocrine circuit that 
incorporates peripheral signaling and the brainstem-hypothalamic pathways. 
 
Figure 1.7: Homeostatic control of food intake by the CNS. The hypothalamus and the brainstem integrate 
signals from the periphery: Cholecystokinin (CCK) released from the GI (gastrointestinal) tract affects the 
NTS (nucleus of the solitary tract) and leptin from the adipose tissue affects AGRP (Agouti-related protein) 
and POMC (proopiomelanocortin) neurons in the hypothalamic arcuate nucleus (ARC). Figure adapted from 
Morton GJ et al. 2014 [92]. 
The fact that OT receptors are present throughout the brain areas controlling 
consumption for energy serves as the neuroanatomical basis suggesting the 
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involvement of OT in satiety processes. The OTr has been found in the DVC and 
the hypothalamus (including the PVN, SON, VMH and LHA). A decrease in energy-
driven food intake has been found in laboratory animals injected with OT and 
synthetic OTr agonists into the cerebral ventricle (ICV) as well into specific sites, 
such as the VMH and NTS [93-95]. The initial article showing anorexigenic effect 
of ICV OT in food-deprived rats was published in the 1990’s by Arletti et al. [81]. 
These authors showed that ICV OT inhibited chow intake in food-deprived and 
food-unrestricted rats. Moreover, ICV OT increased the latency to begin the meal 
and reduced time spent eating. The anorexigenic effects were abolished by a 
pre-treatment with an OTr antagonist. Since that initial report, a number of 
authors have generated data that support the notion of the meal-end, satiety-
related activation of the OT system and the link between the energy status and 
the OT system’s activity. For example, the number of Fos-positive OT neurons in 
the PVN and SON is significantly higher at the end than at the beginning of a 
scheduled meal in rodents [96]. Release of OT into the peripheral circulation 
occurs upon discontinuation of consummatory activity [97]. Real-time PCR 
analyses have revealed that OT system gene expression profile differs in animals 
subjected to various calorie availability regimens [47]. Finally, peripheral, ICV and 
direct site-specific intra-PVN injections of peptides that decrease appetite, such 
as alpha-melanocyte stimulating hormone (alpha-MSH) and glucagon-like 
peptide-1 (GLP-1), stimulate OT signaling [98,99]. Though the main consensus on 
the involvement of OT in feeding control stipulates that OT reduces appetite 
primarily via the central “pool” of its receptor, also peripheral (intraperitoneal; IP) 
injections of OT decrease ingestive behavior [81]. Baskin et al [100] found that 
peripheral injections of OT decrease food intake, but the blockade of the OTr in 
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the hindbrain does not completely abolish peripheral OT-induced anorexia, but 
only somewhat alleviates the hypophagic effects of OT. To some extent, these 
appetite changes might also be secondary to energy metabolism- and adiposity-
related effects induced by the peptide. For example, Maejima and colleagues 
found that peripheral OT in mice reduces not only feeding, but also body weight 
and visceral fat mass, and it ameliorates glucose intolerance [101]. In line with 
those findings, OT has been shown to increase the expression of stearoyl-
coenzyme A desaturase 1, as well as the content of N-oleoyl-
phosphatidylethanolamine, the biosynthetic precursor of the oleic acid-derived 
PPAR-alpha activator, oleoylethanolamide, in the adipose tissue [102].  
1.3.1.2 Stomach distension and osmolality 
The risks posed by stomach distension that exceeds this organ’s capacity as well 
as by ion imbalance (due to salt loading) are critical ingestive behavior-derived 
challenges to homeostasis. In order to prevent these two parameters from 
reaching values that endanger the animal’s well-being, there needs to be a 
feeding regulatory system which will promote an immediate termination of any 
consummatory activity. OT has been suggested to be a component of this 
mechanism.  
In rats, elevated sodium levels or dehydration (resulting in an increase in sodium 
concentration) increase neurohypophyseal OT secretion and promote concurrent 
inhibition of food intake [103]. Indeed, obliteration of the periventricular area of 
the rostral AV3V region in rats decreases their drinking response after an 
injection of hypertonic saline and decreases the posterior pituitary OT release 
[103]. ICV administration of OT decreases salt consumption and this effect is 
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reversible by an OTr antagonist [104]. Genetic deletion of the OTr promotes a 
decrease in salt consumption [105, 106]. Elevated OT plasma levels in rats lead to 
an increase the in urinary sodium concentration, the effect that can be abolished 
by an OTr blockade [107]. Furthermore, mice overexpressing OT mRNA consume 
two time less sodium compared to their wild-type (WT) counterparts [108]. One 
of the mechanisms underlying this effect might be the relationship between OT 
and angiotensin in facilitating renal sodium excretion and maintaining osmotic 
balance. For example, it has been shown that inhibition of OT release stimulates 
angiotensin secretion [104].  
OT neuronal activity is elevated also upon increase in stomach distension (when 
large amounts of food are introduced into the stomach) and coincides with meal 
termination [109]. Information on the GI (gastrointestinal) motility is relayed into 
the CNS by the vagal afferents, eventually reaching OT neuronal populations in 
the hypothalamus [110]. OT affects gastric motility via NTS and DMN pathways 
[111,112]. ICV OT injections or electric stimulation of the PVN have been shown 
to dose-dependently decrease gastric motility in rats, the effect reversed by an 
OTr antagonist [113]. 
1.3.1.3. Oxytocin and aversion / toxicity 
Aside from nutritive and non-nutritive (and, in both cases: palatability affecting) 
components, food may contain toxic chemicals. Ingestion of such substances 
may lead to malaise and sickness and, under some circumstances (depending on 
the amount ingested as well as physiological and pathophysiological status of the 
organism, to name a few), it may lead to serious health consequences. 
Furthermore, not only toxins per se, but also some nutritive and non-nutritive 
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food components – especially at high volumes and/or concentrations (and when 
ingested rapidly) - can produce toxic-like effects. The most desirable behavioral 
response upon inadvertent consumption of sickness producing tastants is an 
abrupt discontinuation of consummatory activity and – if a given tastant has 
easily distinguishable characteristics – learning to avoid this tastant in the future.  
In the laboratory setting, the process of malaise/sickness-driven anorexia and 
subsequent avoidance of foods associated with the development of unpleasant 
GI sensations, is typically studied by employing a conditioned taste aversion (CTA) 
paradigm. A CTA is a classical Pavlovian phenomenon in which avoidance of a 
tastant upon subsequent presentations is generated by pairing the initial 
exposure to this tastant with an injection of a GI discomfort inducing substance 
[114], such as cholecystokinin (CCK), copper sulphate [115, 116] or – most 
frequently used - lithium chloride (LiCl) [117-119].   
Administration of CTA inducing agents activates a vast array of neural and 
neuroendocrine pathways, and these circuits include OT. It has been shown that 
systemic infusion of LiCl induces c-Fos immunoreactivity in several brain regions, 
including the AP, NTS, lateral parabrachial nucleus, SON, PVN, and central 
nucleus of the amygdala (CeA). Vagal afferents reaching the NTS and DMNV 
mediate the neural input relevant to, among others, changes in gastric motility 
caused by toxins. One of neuronal populations affected by the vagal input 
contains GLP-1 synthesizing cells in the NTS that project directly to the 
hypothalamus and terminate in the vicinity of OT perikarya [120]; GLP-1 
receptors are present on OT neurons and their ligands stimulate OT cells [121]. 
GLP-1 promotes CTAs, whereas antagonism of GLP-1 receptors alleviates 
aversive consequences [122]. Notably, GLP-1 NTS neurons are activated by LiCl. 
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Concurrently, in the SON and PVN of animals subjected to an aversive treatment, 
OT cells show a dramatic increase in colocalization with c-Fos, an immediate-
early gene product [123]. This elevated OT neuronal activity is accompanied by a 
surge in circulating OT [124,125].  
Due to the unique neuroanatomical distribution of OT neurons, for many years 
OT was viewed as the “final component” of central pathways that mediate CTA 
and some authors even doubted whether OT is a player in CTA processing at all 
or just a mere indicator of activity within aversion-related neural networks [126, 
127] [128, 129]. For example, AP-facilitated chemoreception allows the toxin to 
be recognized directly by the brainstem [130]. Ablation of this particular 
hindbrain site critically impairs the animal’s ability to develop a proper CTA 
response, though hypophagia in LiCl-treated AP-lesioned rats remains (and so 
does the increased OT tone upon toxin administration) [131]. Altogether, toxin-
derived activation of the DVC engages downstream pathways that include 
hypothalamic OT cell populations [123,132]. As to whether OT is a key player in 
CTA was addressed in the study in which the effect of OTr blockade on CTA 
acquisition was established. It revealed that a BBB-penetrant OT antagonist, L-
36,899, prevents the development of CTA, thus pointed to fact that an available 
OTr underlies the ability of the organism to acquire aversion. 
1.3.2 Oxytocin and the reward system: emphasis on feeding for 
pleasure 
Energy needs are not the sole motivation underlying ingestive behavior. One of 
the main reasons supporting the drive to consume food is pleasant taste. This 
pleasure of eating comes from activating appropriate taste receptors, from 
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certain postabsorptive processes [133] and – most importantly – from increasing 
activity of a specific set of brain sites that promote eating for pleasure, 
collectively referred to as the reward system [134, 135]. Two key components of 
the reward system are the Acb and the VTA. They contain cells expressing reward 
mediators, such as opioids, dopamine, serotonin and endocannabinoids [136-
142]. Ingestion of palatable food increases the activity of the reward areas and 
affects the expression of genes associated with feeding reward in this circuit 
[143].  
There are neuroanatomical and functional foundations underlying the 
relationship between reward sites and the OT system. The Acb and VTA express a 
high density of OTr, and PVN OT neurons have been shown to innervate Acb and 
VTA [20, 144, 145]. OT terminals have been found in the vicinity of perikarya and 
axons of mesolimbic neurons [144-146]. Notably, this cross-link with the 
mesolimbic reward system and the OT system is reciprocal. For example, various 
subtypes of opioid receptors have been detected in the SON and PVN [147, 148], 
hypothalamic OT neurons express opioid receptors [149, 150] and the release of 
OT and activity of OT cells is affected by direct administration of OTr ligands [47].  
The cross-link between OT and reward appears to be broad and include non-
feeding rewards: from naturally pleasant contexts of social and reproductive 
behaviors to intake of alcohol and administration of drugs of abuse). Cocaine 
treatment has been found to change OTr binding density in the bed nucleus of 
the stria terminalis [151]. Direct AcbC infusions of OT decrease 
methamphetamine-seeking in rats [152]. It also attenuates methamphetamine-
induced conditioned place preference [153]. Qi et al. investigated the effects of 
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OT on methamphetamine-induced extracellular levels of glutamate and γ-
aminobutyric acid (GABA) in the medial prefrontal cortex. They found that OT 
decreases glutamate release and increases γ- GABA in this site, and a selective 
inhibitor of OTr, antagonizes these effects of the native OT molecule [154]. Acb 
OT administration hampers the development, maintenance, and primed 
reinstatement of alcohol-induced conditioned place preference [155]. ICV OT in 
mice promotes the development of a conditioned social preference [156].  
While the role of OT in the regulation of energy homeostasis is well established, 
the concept of a possible function in feeding reward has emerged relatively 
recently. Knockout (KO) mouse studies have shown that deletion of the OT gene 
leads to overconsumption of palatable sucrose solutions regardless of whether 
sugary tastants are offered during the light or dark phase of the LD cycle or 
during enhanced anxiogenic conditions [157, 158]. OT KOs given a choice 
between two tastants (water was used as a control ingestant in those two-bottle 
tests), display a greater preference for sucrose and for other palatable 
carbohydrate solutions even if these solutions are not sweet (e.g., cornstarch 
emulsion). The OT-null murine strain also drinks more saccharin (a non-caloric 
and non-carbohydrate sweetener) [157]. Higher preferences for palatable 
foods/solutions in OT KOs do not expand onto fat: a similar intake of a palatable 
lipid emulsion, Intralipid, was observed in KOs and the wild-type (WT) controls 
[159].  
The OT KO mouse data are largely consistent with the outcomes of studies 
utilizing non-KO animal models. For example, OT mRNA is upregulated in the 
hypothalamus of rats eating scheduled, volume-unrestricted, sugary diet 
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compared to standard food [160]. Immunohistochemical comparison of 
hypothalamic OT neuronal activity levels (through detecting c-Fos-OT co-
localization) shows a significantly higher proportion of activated hypothalamic 
OT neurons in sucrose than fat consuming animals. It should be noted that 
regardless of a composition of a meal, activation of OT neurons is much higher at 
the time of termination rather than initiation of a meal, which underscores the 
role of central OT as a general satiety mediator [47]. Moreover, injections of a 
non-peptide OTr antagonist, L-368,899, in choice and no-choice feeding 
scenarios [161], increase carbohydrate intake, without affecting fat consumption 
[47]. Finally, a recent report by Mullis et al. showed that direct VTA 
administration of OT decreases palatability-driven sucrose consumption and the 
effect is reversible by a pre-treatment with L-368,899. The same group of 
investigators found that blockade of the OTr in the VTA leads to 
overconsumption of sugar [162]. Despite the fact that another key reward site, 
the Acb, expresses the OTr in both the shell (AcbSh) and core (AcbC) subdivisions 
[163,164], there has been no attempt to define whether OT acting through this 
region affects food intake. 
Finally, one should take into consideration that any behavior driven by reward, 
including food intake, is heavily influenced by social environment in which an 
individual animal is immersed. This social context component – depending on its 
quality (e.g. the place in hierarchy or the presence/absence of antagonistic 
relations) has a capacity to shift responsiveness to rewarding stimuli. For 
example, in a conditioned place preference paradigm, preference for cocaine can 
be changed by social interaction [165]; lesions of the AcbC induce preference for 
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the social compartment, whereas lesions of the AcbSh - for the cocaine 
compartment [166]. Rats maintained in a social setting consume more alcohol 
than when they are single-housed [167]. Also, subordinate rodents or rodents 
subjected to frequent social defeat scenarios, display enhanced appetite and 
obesity [168-170]. Particular caution should be applied when analyzing feeding 
reward-related effects of OT as this neurohormone has been implicated in a vast 
array of social behaviors, such as pair bonding, mother-infant bonding, and social 
approach and recognition [63, 171-173] [174-176]. Initial evidence already points 
to scenarios in which the magnitude of anorexigenic effects of an OTr antagonist, 
L-368,899, depends on social hierarchy in mice [177]. It is unclear though 
whether the reward system itself participates in this socially mediated shift in 
effectiveness of the drug. 
1.4 Oxytocin as an appetite suppressant acting in the wide 
network of central sites: functional relationship between 
oxytocin and gap junction protein, connexin 36? 
Importantly, OT does not act as a sole player in the regulation of homeostatic or 
rewarding aspects of appetite. OT is part of a large network of pathways and 
sites, comprising multiple genes, neurotransmitters, and neuropeptides. The 
ability of OT to effectively modify consumption depends on structural and 
functional integrity of the relevant brain circuits. This structural and functional 
integrity is assured by multiple molecules that include, to name a few, 
cytoskeletal proteins, synaptic molecules, and transcription factors [178-180]. As 
shown in Chapter 4 section 4.1 of this thesis, a subset of gap junctions, i.e. those 
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whose structure relies on the presence of connexin 36 proteins, are critical 
elements whose genetic elimination leads to a broad spectrum of perturbed 
appetite: feeding for energy, feeding for reward and avoidance of tainted foods. 
As OT is involved in the regulation of the very same aspects of food intake, it has 
led me to explore a question presented in detail in Chapter 4 section 4.2 of 
whether there is a functional relationship between OT and Cx36.  
1.4.1. Cx36 gap junction  
A gap junction channel is formed by transmembrane fixation of hexameric 
structures termed connexons. Connexons consist of six membrane proteins 
belonging to the connexin family (Cx; Figure 1.12). Gap junctions allow 
intercellular communication between adjacent cells by permitting the 
bidirectional passage of ions and small molecules [181-186]. Twenty genes code 
for Cxs in mice and 21 in humans [181]. Six Cxs (Cx26, Cx29, Cx30, Cx32, Cx36 and 
Cx43) have been identified in the mammalian CNS, but in the reward system, 
connexin 36 (Cx36) is predominant [187]. Cx36 channels can be targeted 
pharmacologically with quinine as their blocker [188,189]. 
 
 
Figure 1.8: The structure of a gap junction. Figure adapted from Goodenough DA 2009 
[190]. 
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Studies have shown that, aside from reward areas, most endocrine neurons 
contain Cx36 [187], and that Cx36 gap junctions are implicated in maintaining the 
structural and functional integrity of circuits by facilitating the proper control of 
neuropeptidergic and neurohormonal tone [191, 192]. In mesolimbic areas, Cx36 
is expressed in the VTA [193,194] and the Acb [195]. Allison and al. suggested 
that an intercommunication between GABA neurons in the VTA is mediated by 
Cx36 gap junctions [193,196]. Signaling within the networks that encompass 
Cx36 affects ethanol consumption: a recent study in demonstrated that Cx36 KO 
mice consume significantly less ethanol than WTs and this phenomenon is 
associated with an upregulation of the D2 receptor. [196].  Moreover, the 
rhythm oscillation of dopamine neurons regulated by VTA GABA affects the Acb 
and other components of the limbic system [197]. In rats, a decrease of Cx36 
mRNA expression in the Acb occurs after amphetamine and cocaine treatments 
[198,199]. What is unknown at present is whether Cx36 gap junctions are an 
essential component of circuits through which OT reduces appetite. 
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Aims 
 
 
The overarching aim of this doctoral research was to determine whether OT 
suppresses appetite for palatable foods. This project, utilizing mice and rats as 
model organisms, encompassed three specific aims: 
 
Specific Aim 1: Defining a relationship between peripherally administered BBB-
penetrant OTr antagonist and palatable diet intake. Defining whether OTr 
blockade increases the intake of: (a) all or only sweet carbohydrates or (b) any 
sweet food regardless its macronutrient content (Chapter 2). 
 
Specific Aim 2: Defining whether the nucleus accumbens directly mediates the 
effects of OT on appetite and whether intra-accumbal OT modifies feeding for 
energy and/or reward in non-social and social contexts (Chapter 3). 
 
Specific Aim 3: Understanding whether OT affects feeding for reward and/or 
homeostasis when brain circuits through which it acts are devoid of Cx36, a key 
protein that forms gap junctions in neuroendocrine and reward regions (Chapter 
4). 
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Chapter 2 
 
Oxytocin receptor blockade enhances appetite 
for carbohydrates, particularly sucrose 
 
 
Abstract 
Centrally acting oxytocin (OT) inhibits feeding. Recent evidence suggests a link 
between OT and control of carbohydrate and saccharin intake, but it is unclear 
whether OT affects appetite for only carbohydrates, especially sweet ones, or 
sweet tastants regardless of their carbohydrate content. Therefore, a blood-
brain barrier penetrant OTr antagonist, L-368,899, was administered in mice and 
intake of liquid diets containing carbohydrates sucrose, glucose, fructose, 
polycose, or cornstarch or the non-carbohydrate, non-caloric sweetener 
saccharin was studied in episodic intake paradigms: one in which only one 
tastant was available; and the other, in which a choice between a carbohydrate 
(sucrose, glucose, or fructose) and saccharin was given. We also used RT-PCR to 
examine hypothalamic OT mRNA levels in mice given short-term access to 
sucrose, cornstarch, or saccharin. In the no-choice paradigm, L-368,899 
increased the intake of all carbohydrates, whereas its effect on saccharin 
consumption showed only a trend. A 10-times lower dose (0.3 mg/kg) stimulated 
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intake of sucrose than other carbohydrates. In the choice test, a very low 0.1 
mg/kg dose of L-368,899 doubled the proportion of sucrose consumption 
relative to saccharin, but did not affect fructose or glucose preference. OT gene 
expression increased after sucrose and CS but not saccharin exposure compared 
to controls, however a higher level of significance was detected in the sucrose 
group. We conclude that OT inhibits appetite for carbohydrates. Sucrose 
consumption greatly enhances OT gene expression and it is particularly sensitive 
to OTr blockade, suggesting a special functional relationship between OT and 
sugar intake. 
2.1. Introduction 
A neurohormone oxytocin (OT) produced mainly in the hypothalamic supraoptic 
(SON) and paraventricular (PVN) nuclei inhibits food consumption. Central 
infusions of OT reduce chow intake and OT neurons are activated at meal 
termination [1,2].  Large food loads [3-5] , an increase in plasma osmolality [6], 
treatments with emetic agents [7] , and injections with satiety regulating 
neuroactive endogenous substances [3,8,9] increase OT neuronal activity. 
Genetic deletion of the OTr gene underlies obesity in the murine KO strain [10] . 
While the role of OT in consumption-related homeostasis is well established, 
most recent evidence suggests OT is involved in feeding reward. OT appears to 
serve as a cross-link bridging homeostatic and reward-related satiety. OT 
neuronal activity is particularly robust in response to manipulations that reduce 
intake of rewarding foods, e.g. to naloxone injections [11], and it is greatly 
diminished by orexigenic doses of opioid receptor agonists [12]. Long-term 
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habitual consumption of sugar is associated with diminished OT neuronal activity 
in response to a food load, suggesting that OT dysregulation leads to reward-
driven overeating [13]. 
Importantly, initial studies suggest that OT seems to affect preferentially intake 
of those rewarding tastants that are sweet and/or high in carbohydrates. OT KO 
mice display enhanced preference for sugar and other carbohydrates and OT 
gene deletion is also associated with increased appetite for saccharin [13,14]. 
OTr blockade enhances appetite for sucrose [5,14,15]. Central injections of OT 
reduce the intake of the monosaccharide glucose, but only in food-deprived rats 
[4]. To add to the confusion, OTr KOs have unchanged preference for sucrose 
[16]. Furthermore, OT KOs drink elevated amounts of saccharin, but OTr 
blockade in thirsty animals does not increase preference for saccharin in the 
saccharin-vs-water two-bottle test [17]. 
Overall, it is still unclear whether OT affects appetite for only carbohydrates, 
especially sweet ones, or sweet tastants regardless of their carbohydrate content. 
Therefore, we administered a blood-brain barrier (BBB) penetrant, potent and 
selective antagonist of the mouse OTr, L-368,899 [18] to examine its effect on 
the intake of solutions containing sucrose, glucose, fructose, polycose, 
cornstarch (CS) or saccharin. Two paradigms were used: (1) only one tastant was 
available and the dose-response curves were established, and (2) a choice 
between two sweet ingestants, a carbohydrate (sucrose, glucose or fructose) vs. 
non-carbohydrate saccharin, was studied in mice injected with a very low dose of 
the antagonist. We also used real-time PCR (RT-PCR) to examine changes in 
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hypothalamic OT mRNA levels in mice given short-term access to sucrose, CS, or 
saccharin solutions. 
2.2. Methods  
2.2.1. Animals 
Male C57BL/6J mice (26±3 g; AgResearch, NZ), housed individually (LD 12:12; 
lights on at 0700) at 21–22°C, had unlimited access to chow (Teklad) and water 
unless noted otherwise. The procedures were approved by the University of 
Waikato animal ethics committee. 
2.2.2. Effect of OTr blockade on consumption in the no-choice 
single-bottle paradigm  
Animals (n=8/group) were accustomed to having access to palatable 0.1% 
saccharin, 10% sucrose, 30% sucrose, 10% fructose, 10% polycose or 10% glucose, 
given alone, for 2 h (1000–1200 h) per day for 3 days. In the CS study, to 
stimulate intake of the carbohydrate, mice were food-deprived overnight and 
then they received access for 2 h (1000–1200) to a single bottle containing a 10% 
CS suspension (as CS is insoluble in water, 0.3% xanthan gum was added to the 
liquids in this experiment as described previously in [19]). Chow and water were 
removed for the 2-h period. Animals started drinking right after the solution was 
presented and finished within 50 min. On day 4, 5 min prior to solution exposure, 
mice were injected IP with saline or 0.1, 0.3, 1 and 3 mg/kg b.wt. L-368,899 
(Tocris), at a dose range known to affect consumption [5]. Bottles were weighed; 
the amount of the solution consumed was corrected for spillage and reported in 
g/kg of b.wt. One-way ANOVA followed by Fisher’s post-hoc test was used to 
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establish the effect of L-368,899. P values ≤ 0.05 were considered significantly 
different. 
2.2.3. Effect of OTr blockade on sugars vs saccharin preference  
Mice had been pre-exposed to 0.1% saccharin, 10% sucrose, 10% fructose or 10% 
glucose for 24h several days before the beginning of the trials in order to avoid 
neophobia. Animals (n=6/group) were accustomed to having access to two 
bottles for 3 days: one containing saccharin and the other containing (a) sucrose 
or (b) fructose or (c) glucose, for 2 h (1000–1200). Food was removed from the 
hoppers for the 2-h period of tastant presentation. Five min prior to the 
presentation of the bottles, mice were injected IP with saline or 0.1 mg/kg L-
368,899, and the dose of the antagonist was selected as a low, sub-threshold 
dose insufficient to increase the intake of any carbohydrate tested in a single-
bottle paradigm in the no-choice paradigm described above and in previous 
studies (e.g. [5]). The amount of the solution consumed corrected for spillage 
was calculated in g/kg of b. wt. and the data were expressed as % of sweet 
carbohydrate solution (e.g. sucrose) intake in total fluid (e.g. sucrose + saccharin) 
intake. A t-test was used to establish whether L-368,899 affected preference for 
carbohydrate vs non-carbohydrate. P values ≤ 0.05 were considered significantly 
different. 
2.2.4. OT mRNA levels in mice consuming sucrose, CS or saccharin 
On two subsequent days, water bottles were removed 2h before the beginning 
of the dark phase. At lights off, the animals (n=7-8/group) were given access to 3 
ml of water (control) or the 10% CS, 10% sucrose or 0.1% saccharin 
solutions/suspensions (prepared as in 2.2) which represented ca 40% of their 
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night-time water intake. The fluid was consumed by all but 2 mice (1 from the 
water and 1 from the CS group – excluded from the study) between 3 and 4 h. At 
5 h, water bottles were placed back in the cages. We did not observe differences 
in night-time chow (4.3-4.8 g range) and water (4.0-4.7 ml range) intakes 
between the groups. On the second day at lights on, chow and water were 
removed. The animals were decapitated (7:00-8:00), hypothalamic dissected and 
placed in RNAlater (Ambion) overnight (4°C). A standard protocol of sample 
preparation and RT-PCR was followed (details in [5]) and for brevity reasons, only 
the main elements are described herein. Samples were homogenized in TRIzol 
(Ambion); RNA was extracted with chloroform and precipitated in isopropanol. 
After centrifuging, the pellet was washed, air dried, and dissolved in the DNase 
buffer (NEB). The samples were treated with RNase-free DNase I (37°C, 1h; 
Merck) and the absence of genomic DNA was established by PCR of 5% template 
in the PCR mix [MgCl2-free buffer, 50mM MgCl2, Tween, 20mM dNTP, forward 
and reverse primers, Taq polymerase, and MilliQ H2O; 10μl total volume]. 0.5μl 
100ng/μl genomic DNA was added as a positive control, and 0.5μl MilliQ H2O as a 
negative one. The product was analysed with electrophoresis. To synthesize 
cDNA, 5μg RNA samples (concentration determined spectrophotometrically) 
were diluted with MilliQ H2O to 12μl. RNA was reverse transcribed in the Master 
Mix (Promega; 20μl]. Samples were incubated for 1h (37°C), followed by PCR to 
confirm cDNA synthesis. RT-PCR reactions were performed in duplicates; 
negative controls were included. 25ng of sample cDNA template was used per 
primer (OT primer sequences: cggtggatctcggactgaac (fwd) and 
tagcaggcggaggtcagag (rev)). Each RT-PCR (20μl total volume) contained 2μl 
MgCl2-free buffer 10×, 0.2μl 20mM dNTP, 1.6μl 50mM MgCl2, 0.05μl forward and 
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reverse primer (100pmol/μl), 1 μl DMSO, 0.5μl Sybr Green (1:50,000), 0.08μl Taq 
polymerase, and 9.52μl MilliQ H2O. The amplification step included denaturation 
(95°C, 3min), and 40 cycles of denaturing (95°C, 20s), annealing (30s), and 
elongation (72°C, 30s). Expression of four housekeeping genes, β-actin, β-tubulin, 
glyceraldehyde-3-phosphate-dehydrogenase, and ribosomal protein, was used to 
calculate normalization factors (GeNorm). Primer efficiencies were calculated 
with LinRegPCR, and Ct values were corrected for differences in primer 
efficiencies. Differences between groups were analysed with ANOVA followed by 
Fisher’s test with significance set at P ≤ 0.05. 
2.3. Results 
In the no-choice paradigm, L-368,899 increased the intake of all carbohydrates 
(Figure 2.1), including the CS, whereas its effect on saccharin consumption only 
approached significance. A dose as low as 0.3 mg/kg elevated 10% and 30% 
sucrose consumption (10%: 0.3 mg/kg b. wt. p=0.025; 1 mg/kg b. wt. p=0.008; 
30%: 0.3 mg/kg b. wt. p=0.012; 1 mg/kg b. wt. p=0.027). Fructose, glucose, 
polycose and CS intakes were also increased, however the lowest effective dose 
of L-368,899 (3 mg/kg) was ten times higher (fructose: p=0.016 ; glucose: 
p=0.020; polycose: p=0.031; CS: p=0.039). L-368,899 did not affect appetite for 
saccharin; although there was a trend at 3mg/kg (p=0.088).  
In a two-bottle test, mice given access to a sugar (sucrose, glucose or fructose) 
and saccharin were pre-treated with a 0.1 mg/kg dose of L-368,899, sub-
threshold in the no-choice experiment. L-368,899 doubled the proportion of 
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sucrose consumption relative to saccharin (p= 0.006), but had no effect on the 
preference for fructose or glucose versus saccharin (Figure 2.2). 
Hypothalamic OT gene expression (Figure 2.3) was higher in animals exposed to 
sucrose and CS compared to controls, however a higher level of significance was 
detected in the group fed sucrose (p=0.008) than CS (p=0.036). Saccharin 
exposure did not affect OT mRNA levels. 
 
Figure 2.1: The effect of the OTr antagonist, L-368,899, at 0 (vehicle), 0.1, 0.3, 1 and 3 
mg kg/b. wt on the intake of solutions containing (a) 10% sucrose, (b) 30% sucrose, (c) 
10% fructose, (d) 10% glucose, (e) 10% polycose, (f) 0.1% saccharin and (g) 10% CS. * - 
p<0.05; ** - p<0.01 
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Figure 2.2: The effect of the OTr antagonist, L-368,899, at 0 (saline vehicle), 0.1mg kg/b. 
wt on the intake of solutions containing (a) 10% sucrose , (b) 10% fructose, (c) 10% 
glucose ( carbohydrate) vs 0.1% saccharin (non-carbohydrate) expressed as the % of 
carbohydrate solution consumed in the total volume of ingested tastants. ** -p<0.01  
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Figure 2.3: Hypothalamic OT gene expression established with RT-PCR. On two 
consecutive nights, mice were given access to 3 ml of 10% sucrose, 10% cornstarch or 
0.1% saccharin solutions; controls were given water. * - p<0.05; ** - p<0.01 
2.4. Discussion 
The current set of experiments confirms that OT affects appetite for 
carbohydrates and it points to a special functional relationship between OT and 
sucrose intake. Antagonism of the OTr in the no-choice paradigm led to an 
increase in the intake of all carbohydrates, i.e., sucrose, glucose and fructose, 
polycose and CS, but it should be emphasized that the consumption of sucrose 
was induced by the antagonist dose that was 10 times lower than that needed to 
affect intake of the remaining carbohydrates. Importantly, blockade of the OTr 
stimulated appetite for carbohydrates independent of their sweetness and 
rewarding value: bland CS and palatable sweet carbohydrates were ingested 
more avidly after the treatment. This is in concert with the KO animal data in 
which the genetic deletion of the OT gene caused overconsumption of a variety 
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of carbohydrates, including starch [14]. Therefore, a sweet flavor does not seem 
to be a prerequisite underlying the effectiveness of OT in regulating 
carbohydrate-specific satiety and neither is the complexity of their structure (i.e., 
mono-, di- and polysaccharide). Furthermore, the effect of L-368,899 on sucrose 
intake remained even after the three-fold increase in the concentration of 
sucrose in the solution; hence, the link between carbohydrate consumption and 
OT does not appear to be modified by the caloric density of the tastant.  
Aside from the episodic intake of carbohydrates being decreased by OTr 
antagonism, we found that short-term enrichment of the diet with 
carbohydrates (either sucrose or CS) caused up-regulation of the OT transcript in 
the hypothalamus compared to controls. This is in line with the OT mRNA 
findings in sucrose- versus regular diet-exposed rats [20]. Noteworthy, a greater 
increase in our RT-PCR study was found in sucrose- than in CS-fed mice despite 
the same amount of the carbohydrate containing fluid consumed by the 
respective groups.  
Unlike appetite for carbohydrates, saccharin intake was not elevated by OTr 
blockade, though the highest dose of the compound induced the consummatory 
response that showed a trend approaching significance. Also, our RT-PCR 
experiment showed that hypothalamic OT gene expression was not affected by 
short-term saccharin exposure. Though these data are in contrast to OT KO 
murine studies in which saccharin overconsumption was noted [14], they are in 
line with antagonist injection experiments that showed the lack of the effect of L-
368,899 on preference for saccharin in water-deprived mice given a choice 
between the saccharin solution and water [17]. Overall, this suggests that the 
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involvement of the OTr in saccharin intake regulation is not as critical as in 
appetite for carbohydrates, but obviously considering the trend in saccharin 
consumption reported herein and the positive KO mouse data [14], it cannot be 
negated. Importantly, it appears that this is not the sweet flavor (note saccharin 
vs. CS intakes) but rather the carbohydrate content of an ingestant that defines 
the link between OT and feeding control. 
The two-bottle preference tests confirmed the proposed special relationship 
between OT and the control of sucrose intake. The very low dose of L-368,899 
that was found to be insufficient to affect the intake of any of the carbohydrates 
in the no-choice paradigm, increased the preference for sucrose vs saccharin in 
the two-bottle test. It did not affect the relative preference for the other two 
carbohydrates, fructose and glucose, which strengthens the claim that the OTr 
plays a role in sucrose-specific satiety. The fact that there was no change of 
preference for fructose and glucose vs. saccharin implies that calories, at least in 
the relatively energy-dilute liquid diets, are not the causative factor behind the 
shift in preference in the sucrose vs. saccharin scenario.  
In summary, the present study shows that antagonism of the OT receptor 
enhances appetite for carbohydrates and this role is independent from sweet 
flavor. Sucrose consumption greatly enhances OT gene expression and appears 
to be particularly sensitive to the OTr blockade, which strengthens the notion 
that there is a special functional relationship between OT and sucrose intake, 
and suggests that OT may serve as a key neuroregulator of sucrose-specific 
satiety.  
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Chapter 3 
Oxytocin acting via the nucleus accumbens core 
decreases food intake driven by hunger and by 
reward in rats offered a meal in a non-social 
setting 
 
Abstract 
Central oxytocin (OT) promotes feeding termination in response to homeostatic 
challenges, such as excessive stomach distension, salt loading, and toxicity. OT 
has also been proposed to affect feeding reward by decreasing consumption of 
palatable carbohydrates and sweet tastants. As the OT receptor (OTr) is 
expressed in the nucleus accumbens core (AcbC) and shell (AcbSh), a site 
regulating diverse aspects of eating behavior, we investigated whether OT acting 
therein affects appetite in rats. First, we examined whether direct AcbC and 
AcbSh OT injections affect hunger- and palatability-driven consumption. We 
found that only AcbC OT infusions decrease deprivation-induced chow intake and 
reduce consumption of palatable sucrose and saccharin solutions in non-
deprived animals. These effects were abolished by a pre-treatment with an OTr 
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antagonist, L-368,899, injected in the same site. AcbC OT at an anorexigenic dose 
did not induce a conditioned taste aversion, which indicates that AcbC OT-driven 
anorexia is not caused by sickness/malaise. The appetite-specific effect of AcbC 
OT is supported by the real-time PCR analysis of OTr mRNA in the AcbC which 
revealed that food deprivation elevates OTr mRNA expression, whereas 
saccharin solution intake decreases OTr transcript levels. We also used c-Fos 
immunohistochemistry as a marker of neuronal activity.  We found that AcbC OT 
injection increases activation of the AcbC, hypothalamic paraventricular (PVN) 
and supraoptic (SON) nuclei, and – within the PVN and SON – it increases the 
percentage of activated OT cells. Finally, considering the fact that OT plays a 
significant role in social behaviour, we examined whether offering animals a 
meal in a social setting would modify their hypophagic response to AcbC OT 
injections. We found that a social context abolishes anorexigenic effects of AcbC 
OT. We conclude that OT acting via the AcbC decreases food intake driven by 
hunger and by reward in rats offered a meal in a non-social setting.   
3.1. Introduction 
Oxytocin (OT) promotes feeding termination mainly through central mechanisms 
[1, 2]. An increased level of OT neuronal activity and OT release occurs at the end 
of a meal and in response to excessive plasma osmolality and stomach distension 
[3,4]. In 1990, Arletti et al showed that intracerebroventricular (ICV) OT 
injections cause a marked reduction in food intake [5]. Since that initial study, 
many authors have confirmed the anorexigenic effect of OT and have begun 
identifying brain sites mediating OT-driven food termination [6]. The majority of 
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work has focused on the brainstem component of the circuitry: OT infusions in 
the nucleus of the solitary tract (NTS) [2] inhibit feeding, and the activity within 
the OT NTS-PVN pathway has been functionally linked with neuroendocrine 
regulators of energy homeostasis (especially those involved in gastrointestinal 
and osmotic control), including cholecystokinin (CCK), glucagon-like-peptide-1 
(GLP-1), and peptide YY (PYY) [7]. Furthermore, OT administration in the 
ventromedial hypothalamic nucleus (VMH) acutely decreases chow intake and 
increases energy expenditure in rats [7, 8].  
OT acting outside the brainstem-hypothalamic pathways also promotes 
hypophagia. Mullis et al found that OT administered in the ventral tegmental 
area (VTA) in rats causes a dose-dependent decrease in deprivation-induced 
chow intake and affects sucrose consumption [9]. Their findings were in 
agreement with other reports suggesting that OT appears to serve as a cross-link 
between mechanisms that bridge termination of consumption due to 
“homeostatic” (i.e., related mainly to stomach distension and osmolality) and 
palatability-specific (i.e., related to sweet flavor and carbohydrate) satiety. For 
example, OT knockout mice consume sweet carbohydrates and saccharin less 
avidly than wild-type controls. Pharmacological blockade of the OTr elevates 
intake of sweet tastants in sated mice [10], whereas OT administration reduces 
intake of glucose in food-deprived rats [11]. Opioid receptor antagonist 
injections that decrease palatable sucrose intake also activate OT neurons [12], 
and OT gene expression is increased after a high sugar diet intake in rats [13].  
Despite the presence of the OTr in the core (C) and shell (Sh) subdivisions [2, 14, 
15]  of the nucleus accumbens (Acb), another key extrahypothalamic appetite 
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regulating area, thus far there have been no reports delineating potential 
involvement of this region in mediating OT’s effects on food intake.  Extensive 
studies on the relationship between AcbSh and feeding control have shown that 
opioid and dopamine signaling in the AcbSh affects particularly hedonics of 
consumption [15, 16], whereas glutamate and GABA in this subdivision regulate 
also energy intake [17] [18]. Less is known about AcbC, though several authors 
have reported that GLP-1 in the AcbC affects meal size and rewarding aspects of 
food consumption [19-21].  
In the current set of studies, we investigated whether OT acting in the Acb 
affects appetite in rats. First, we examined whether AcbC and/or AcbSh 
injections of OT decrease hunger- and palatability-driven consumption. Once we 
established that only the AcbC injections produce hypophagia, we focused on 
providing a more detailed characterization of the role of the AcbC OT in feeding 
regulation.  A conditioned taste aversion (CTA) paradigm was used to examine 
whether AcbC OT-driven anorexia is related to malaise. Considering the fact that 
OT plays a significant role in social behavior [22-24], we also examined how OT 
injected in the AcbC affects feeding in a social setting. Finally, we determined 
changes in c-Fos immunoreactivity in feeding-related brain sites after AcbC 
infusion of an anorexigenic dose of OT, and we analyzed changes in OTr mRNA 
expression in rats exposed to food deprivation and to a palatable diet.  
3.2. Materials and Methods 
3.2.1. Animals. Adult male Sprague-Dawley rats weighing ca 335 g at the 
beginning of the experiment were housed individually in plastic cages with LD 
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12:12 (lights on at 07:00; temp.: 20–22 °C). Tap water and standard laboratory 
chow (Teklad) were available ad libitum unless noted otherwise. All procedures 
received prior approval from the University of Waikato ethics committee. 
3.2.2. Surgeries. Rats used for intracranial infusion studies were anesthetized 
with IP ketamine (100 mg/kg) / xylazine (20 mg/kg) and equipped unilaterally 
with a 7.5-mm stainless steel cannula (23-gauge, Plastics One, Australia) aimed at 
the AcbC or AcbSh. Stereotaxic coordinates for the AcbC were: 1.5 mm 
anteroposterior; -1.4 mm mediolateral to bregma; -5.5 mm dorsoventral to skull 
surface, and for the AcbSh: 1.5 mm, -0.8 mm; -7 mm, respectively. The injector 
protruded 0.5 mm below the tip of the cannula. Dental cement was used to 
secure the cannula to three screws inserted in the skull. Rats received Caprofen 
(5mg/ml, SC) immediately following the surgery. They were allowed to recover 
for at least 7 days. After the completion of all behavioral experiments, rats were 
sacrificed and cannula placement was assessed in immunohistochemically 
processed brains (see Section 3.2.11). 
3.2.3. Injections. OT (Phoenix) and OTr antagonist (L-368,899; Tocris) were 
injected with Hamilton syringes in a volume of 0.5μl over 1 min. Drugs were 
dissolved in isotonic saline.  
3.2.4. Effect of OT in the AcbC versus AcbSh on deprivation-induced 
chow intake. Rats were deprived of chow overnight. Five min before food 
presentation (10:00), they were injected in the AcbC or AcbSh with 0 (saline), 0.3, 
1 and 3μg OT (n=8-9/group). Chow was weighed before and 2, 4 and 24 h after 
the treatment. 
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3.2.5. Effect of OT in the AcbC versus AcbSh on the intake of sweet 
palatable solutions. We followed a similar protocol as in (PMID: 24893201). 
In brief, animals (n=8-12/group) were accustomed to having access to a bottle of 
a 10% sucrose solution for 2 h/day (10:00–12:00) for 3 days (chow and water 
were removed for the 2 h). On day 4, just before sucrose presentation, rats were 
injected in the AcbC or AcbSh with 0 (saline), 0.1, 0.3, 1 and 3μg OT (n=8/group) 
and the amount of consumed solution was established 2 h post-injection. The 
same approach was employed to study the effect of OT on 0.1% saccharin intake, 
however, 0, 0.01, 0.03, 0.1, 0.3 and 3μg doses of OT were used.  
3.2.6. Effect of AcbC OTr antagonist pre-treatment on the ability of 
AcbC OT to decrease deprivation-induced feeding. Rats were deprived 
of chow overnight. Just prior to regaining access to chow (10:00), they received 
two AcbC injections spaced 10 min apart: (a) saline followed by saline; (b) saline 
followed 1μg OT (lowest effective OT dose based on Exp 1); (c) 0.3μg L-368,899 
followed by 1μg OT; (d) 1μl L-368,899 followed by 1μg OT; and (e) 3μg L-368,899  
followed by 1μg OT (n=7/group). Food intake was measured 2 and 4 h post-
injection. L-368,899 doses were chosen based on previous reports [10]. 
3.2.7. Effect of AcbC OTr antagonist pre-treatment on the ability of 
AcbC OT to decrease consumption of sucrose and saccharin 
solutions. As described for Exp 2.5, animals were accustomed to having access 
to a bottle of a 10% sucrose (or 0.1% saccharin) solution for 2 h/day (10:00–
12:00) for 3 days. On day 4, just before sucrose presentation, rats were double-
injected (10 min apart) in the AcbC with (a) saline followed by saline, (b) saline 
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followed 0.3μg OT, (c) 1μl L-368,899 followed by 0.3μg OT. Before the 0.1% 
saccharin presentation, rats were treated in the same manner except for the 
doses of OT and L-368,899, which were 0.03μg and 3μl, respectively (n=7-
8/group). Consumption was measured 2 h post-injection. 
3.2.8. Effect of AcbC OT on deprivation-induced and palatability-
induced consumption in the social context. In order to assess the effect 
of AcbC OT on food intake in the social context, single-housed rats were 
episodically placed in a predictable social setting in which food intake occurred. 
We designed an apparatus which was a subdivided standard Macrolon cage with 
a metal grid lid (with an overhead food hopper and bottle holder on one side of 
the cage). It was subdivided into two identical chambers (L48cm x W19cm) by a 
transparent, Plexiglas partition wall, containing multiple ø1.5cm round openings, 
which allowed the rats placed simultaneously in each chamber for incomplete 
socialization (visual, auditory, olfactory and partial tactile) devoid of major direct 
interactions (especially antagonistic ones) that could impair animals’ ability to 
access food. All animals used in these studies were accustomed to being in the 
apparatus and having food presented therein in at least 8 separate 1-h training 
sessions (starting between 10:00 and 12:00). The chambers were wiped with 
ethanol after each use. During the pharmacological studies, only one of the two 
animals simultaneously present in the apparatus received an injection of saline 
or OT. 
To examine the effect of OT on deprivation-induced feeding in the social setting, 
animals had chow removed overnight. Afterwards, two rats were placed 
simultaneously in the social context apparatus (one rat per chamber) wherein 
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pre-weighed chow was put in the hopper. Just prior to the session, one of the 
two rats received an injection of 0 (saline), 1 or 3μg OT (n=8-10/group) in the 
AcbC, and food intake was measured 1 h later. 
To assess the effect of OT on intake of sweet palatable tastants in the social 
setting, rats were accustomed to getting episodic access to a single bottle of 10% 
sucrose or 0.1% saccharin solution similarly to the non-social scenario described 
in Section 2.5.  On the experimental day, two rats were placed simultaneously in 
the social context apparatus (one rat per chamber) wherein they gained access 
to individual pre-weighed bottles containing a sweet solution. Just prior to the 
session, one of the two rats received an injection of saline) or OT. 0.03, 0.1, 0.3 
and 1μg doses of OT were injected in the sucrose-exposed animals, whereas 0.03, 
0.1 and 0.3μg OT, in rats given the saccharin solution (n=6-8/group). Bottles were 
collected and weight before and after 1h post-injection. 
3.2.9. AcbC OT and CTA development. Rats were accustomed to having 
access to water for 2 h (11:00–13:00) per day for 3 days. Food was removed from 
hoppers for the 2-h period of scheduled fluid presentation. On day 4, rats were 
given a novel 0.1% saccharin solution instead of water for 60 min. Afterwards 
they received an AcbC injection of saline or 1μg OT (an effective anorexigenic 
dose based on feeding experiments) (n=5/group). On day 5, a two-bottle 
preference test (saccharin versus water) was used to assess acquisition of a CTA 
to the saccharin solution [56-58]. Bottles were weighed and percentages of the 
saccharin solution intake (out of cumulative, i.e. saccharin plus water, intake) 
were calculated. 
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3.2.10. Consummatory behavior data analysis. All food intake 
experiments utilizing single OT injections were analyzed with one-way ANOVA 
followed by Fischer’s post-hoc test. In the double injection experiments, first the 
effect of OT against saline control was confirmed with a t-test and then the 
effect of the antagonist pretreatment on OT-induced anorexia was determined 
with one-way ANOVA followed by Fischer’s post-hoc test. The CTA OT versus 
saline two group comparison was done with a t-test. Values were considered 
significant when p<0.05. 
3.2.11. c-Fos immunoreactivity in feeding-related brain sites in 
response to AcbC OT injection. Rats received a single injection of saline or 
3μg OT in the AcbC (n=5-6/group). Injections were performed between 10:00 
and 12:00. Food and water were removed immediately after the drug treatment. 
60 min later, animals were anesthetized and perfused with 50 ml of saline 
followed by 500 ml of 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 
7.4). Brains were excised and postfixed overnight in PFA (4°C). Coronal 60-μm 
Vibratome (Leica) sections were processed for c-Fos or c-Fos+OT immunostaining. 
The tissue was treated for 10 min in 3% H2O2 in 10% methanol (in TBS, pH 7.4) 
and incubated overnight at 4°C in the goat anti-c-Fos antibody (1:2000; Santa 
Cruz). Subsequently sections were incubated for 1h in the rabbit-anti-goat 
antibody (Vector) and then in the avidin-biotin complex (1h; Vector). Peroxidase 
was visualized with 0.05% diaminobenzidine, 0.01 H2O2, and 0.2% nickel sulfate 
(all Sigma). All incubations were done in a mixture of 0.25% gelatin and 0.5% 
Triton X-100 (Sigma) in TBS. Intermediate rinsing was done with TBS. Following 
the completion of c-Fos staining, sections were further processed for 
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visualization of OT. The procedure was similar to that used to identify c-Fos. 
However, rabbit anti-oxytocin was used as the primary antibody (1:15000; 
Millipore, Temecula, CA), and nickel sulfate was omitted from the DAB solution 
so as to obtain a brown color. Sections were mounted on gelatinized slides, dried, 
dehydrated in ethanol, soaked in xylene, and embedded in Entellan (Merck). The 
number of c-Fos positive nuclei was counted bilaterally in all regions of interest 
(4-5 sections containing a given site per animal) except for the AcbC where c-Fos 
IR was assessed ipsilaterally to the cannula, using Scion Image software. 
Densities of Fos positive nuclei (per mm2) were averaged per rat and then per 
group. In the double staining analysis, the following estimates were assessed per 
section and then per region: the total number of OT neurons and the number of 
OT neurons positive for c-Fos. Cells were counted bilaterally, and the percentage 
of OT neurons containing c-Fos-positive nuclei was tabulated. A t-test was used 
to determine differences between the two groups (significance set at p<0.05). 
3.2.12. Effect of regular diet versus sweet diet and regular diet 
versus food deprivation on OTr gene expression levels in the AcbC 
In order to assess the effect of sweet palatable solution exposure on AcbC OTr 
mRNA levels, rats were given access to either chow and water (control) or to 
chow and 0.1% saccharin solution (instead of water) for 48h (n = 8/group). In a 
separate experiment assessing the effect of food deprivation on OTr mRNA levels, 
rats were either maintained on ad libitum access to chow and water (control) or 
chow was removed for 24 hours prior to decapitation (n = 8/group). 
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The animals were decapitated (10:00-12:00) and the AcbC was collected excised, 
immersed in RNAlater (Ambion), kept at room temperature for 2 h and, 
thereafter, stored at −80 °C (as described in our earlier publication [13]).  
3.2.12.1. RNA isolation, cDNA synthesis and real-time PCR. Samples were 
sonicated in TRIzol (Invitrogen), chloroform was added to the homogenate, 
which was then centrifuged at 10,000 × g at 4°C for 15 min. The water phase was 
transferred to a new tube, and RNA was precipitated with isopropanol. The 
pellets were washed with 75% ethanol, air dried, and dissolved in RNAse-free 
water. DNA was removed with DNAse I treatment (Roche; 4 h, 37 °C), and the 
enzyme was inactivated by heating the samples at 75°C for 15 min. The absence 
of genomic DNA was determined by the PCR analysis with primers for the RNA 
extractions with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) on the 
DNAse-treated RNA. RNA concentration was measured with a NanoDrop®ND-
1000. cDNA was synthesized with MMLV reverse transcriptase (GE Healthcare), 
using random hexamers as primers according to the manufacturer's 
specifications. cDNA was analyzed with a MyIQ thermal cycler (Bio-Rad). Each 
rtPCR reaction with a total volume of 20 μl contained cDNA synthesized from 
25 ng total RNA, 0.25 M each primer, 20 mM Tris/HCl (pH 8.4), 50 nM KCl, 4 mM 
MgCl2, 0.2 mM dNTP, SYBR Green (1:50000). Reactions were performed with 
0.02 U/l Taq DNA polymerase (Invitrogen) under the following conditions: initial 
denaturation for 4 min at 95 °C, followed by 50 cycles of 15 s each at 95 °C, 30 s 
at 55–62 °C (i.e. at the optimal annealing temp. for each primer pair), and 30 s at 
72 °C. This was followed by 1 min at 55–62 °C (optimal annealing temp.) and a 
melting curve with 84 cycles of 10 s at 55°C increased by 0.5°C per cycle. All 
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experiments were done in duplicates. The measurements where the threshold 
cycle (Ct) values between the duplicates had a difference of over 0.9 were 
repeated. A negative control for a given primer pair and a positive control with 
25 ng of genomic DNA was included on each plate. The following HKGs were 
used to define normalization factors:  GAPDH, β-tubulin (TUB), ribosomal protein 
19 (RPL19), histone H3 (H3), cyclophilin (CYCLO), β-actin (ACT) and succinate 
dehydrogenase complex, subunit B (SUCB) (as in 19022308). The sequence of the 
OTr primer pairs were as follows: TTCTTCTGCTGCTCTGCTCGT (fwd) and 
TCATGCTGAAGATGGCTGAGA (rev). 
3.2.12.2. Data analysis and relative expression calculations. The MyiQ software 
v. 1.04 (Bio-Rad) was used to analyze qPCR data and derive Ct values. Melting 
curves were analyzed to confirm that one product was amplified and that it was 
significantly shifted compared to the melting curve for the negative control. The 
sample Ct values were analyzed further if the difference between those and the 
negative control exceeded 3; otherwise, the transcript was considered not to be 
expressed. Normalization factors were calculated with GeNorm. LinRegPCR was 
employed to calculate PCR efficiencies for each sample. Grubb's test (GraphPad) 
was used to identify and remove outliers and calculate average PCR efficiencies 
for each primer pair. Differences in OTr expression between groups were 
analyzed with a t-test, and p < 0.05 was used as the criterion of statistical 
significance. 
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3.3. Results 
We have found that direct AcbC (Figure 1-2), but not AcbSh (Figure 3.1 E F G), 
injections of OT affect food intake. Administration of 1 and 3 µg OT in the AcbC 
decreased deprivation-induced cumulative chow intake (Figure 3.1 A-B) by 
approximately 35-40% at 2 h (1 µg P=0.028; 3 µg P=0.019) and 4 h (1 µg P=0.006; 
3 µg P=0.004) post-injection. There was no effect on food consumption at 24h 
(data not shown) or water consumption at 2, 4 or 24 h (Table 3.1).  
In non-deprived rats stimulated to eat by palatability of a diet, AcbC infusions of 
1 µg and 3 µg OT decreased sucrose solution intake by ca 50% (P=0.017 and 
P=0.045, respectively). Saccharin solution consumption was decreased to a 
similar degree by OT, however, lower doses were needed to cause the effect: 
0.03 µg (P=0.03), 0.1 µg (P=0.026), 0.3 µg (P=0.025), and 1 µg (P=0.027; Figure 
3.1 C-D). 
Our CTA study showed that AcbC administration of an anorexigenic 1-µg dose of 
OT before presentation of the novel 0.1% saccharin solution did not produce 
learned avoidance of saccharin in the subsequent two-bottle choice test (Figure 
3.1 H).  
The anorexigenic action of AcbC OT was reversed by a pre-treatment with an OTr 
antagonist. In overnight-deprived rats, 1 and 3 µg of L-368,899 counteracted the 
effect of OT at 2 h (3 µg, P=0.042) and 4 h (1 µg, P=0.025; 3 µg, P=0.016) post-
injection (Figure 3.2 A B).  The antagonist abolished the effect of OT on the 
intakes of the sucrose (P=0.030) and saccharin (P=0.04) solutions (Figure 3.2 C D). 
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Furthermore, while OT-induced short-term anorexia was apparent in single-
housed animals stimulated to eat either by hunger or by palatability, AcbC 
infusions of OT at doses effective in the aforementioned scenarios did not affect 
hunger- or reward-driven consumption in rats subjected to the social context of 
a 1-hour meal (Figure 3.3).  
Our c-Fos study revealed that AcbC infusion of 3 µg OT increased activation of 
the AcbC itself (P=0.008) as well as two other sites belonging to a widespread 
central network regulating appetite:  the PVN (P=0.029) and the SON (0.036; 
Figure 3.4). Our double staining for c-Fos and OT revealed an AcbC OT-induced 
increase in the percentage of activated OT cells in both sites (PVN, p=5.6E-5 and 
SON, p=4.5E-6; Figure 3.5). 
Finally, using real-time PCR, we found that expression of the OTr mRNA in the 
AcbC is significantly higher in food-deprived rats compared to ad libitum-fed 
animals (P=0.033) and it decreases in rats given 48-h access to a saccharin 
solution compared to standard diet-fed rats (P=0.045; Figure 3.6) 
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Figure 3.1: The effect of OT injections (doses in µg) in the AcbC and AcbSh on 
consummatory behavior in rats. (A) The effect of AcbC OT on deprivation-induced chow 
intake 2h and (B) 4h post-injection. (C) The effect of AcbC OT on the intake of 10% 
sucrose solution and (D) 0.1% saccharin solution. (E) The effect of AcbSh OT on 
deprivation-induced chow intake 2h post-injection. (F) The effect of AcbSh OT on the 
intake of 10% sucrose solution and (G) 0.1% saccharin solution. (H) Preference for a 
saccharin solution in a two-bottle preference test (saccharin versus water) was assessed 
to determine whether AcbC OT promotes acquisition of a CTA.   * - p<0.05; ** - p<0.01; 
***p<0.005. 
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Figure 3.2:  The effect of AcbC OTr antagonist (ORA: L-368,899) pretreatment on the 
ability of AcbC OT to reduce feeding. Deprivation-induced chow intake was measured  
2h (A)  and 4h (B) after a double injection of saline + saline, saline + 1 µg OT, 0.3,1,3 µg 
ORA + 1 µg OT. (C) Intake of 10% sucrose solution was determined 2h after AcbC double-
injection of saline + saline, saline + 0.3 µg OT, and 1 µg ORA + 0.3 µg OT. (D) Intake of 0. 
1% saccharin solution was measured 2h after AcbC double-injection  of saline + saline, 
saline + 0.03 µg OT, 3 µg ORA + 0.03 µg OT. * - p<0.05; ** - p<0.01; ***p<0.005. 
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Figure 3.3: The effect of AcbC OT (doses in µg) on consummatory behavior of rats 
offered a meal in a social context. (A) Deprivation-induced chow intake 1 h post-
injection. (B) 10% sucrose solution intake and (C) 0.1% saccharin solution intake 1h post-
injection.  
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Figure 3.4: c-Fos immunoreactivity in feeding-related brain sites 1 hour after an AcbC 
injection of OT vs saline. The arrow indicates the injection site. Shell and core of nucleus 
accumbens, AcbC / AcbS; ventral tegmental area, VTA; central nucleus of the amygdala, 
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CNA; basolateral amygdala, BLA; dorsal motor nucleus of the vagus, DMNV; nucleus of 
the solitary tract, NTS; area postrema, AP; paraventricular hypothalamic nucleus, PVN; 
supraoptic nucleus, SON; dorsomedial nucleus, DMH, ventromedial nucleus, VMH; 
lateral hypothalamic area, LHA; arcuate nucleus, ARC; optic tract, otr; 3v, third ventricle. 
* - p<0.05; ** - p<0.01; scale bar – 0.1 mm. 
 
Figure 3.5: Co-localization of c-Fos and OT in the paraventricular (PVN) and supraoptic 
(SON) nuclei of rats injected in the AcbC with OT vs saline. *** - p<0.001. 
 
Figure 3.6: Expression of OTr mRNA in the AcbC. (A) The effect of chow deprivation 
versus ad libitum chow access. (B) The effect of 48-h exposure to 0.1% saccharin 
solution in addition to standard chow versus water and standard chow. Gene expression 
was assessed with real-time PCR.  *P < 0.05.  
 
108 
 
Table 3.1: The effect of the OT injected in the AcbC at saline ( vehicle), 0.3, 1 and 3μg on 
water intake, 2h, 4h and 24h  post injection. The injections were performed after an 
overnight deprivation of regular chow and just prior to 2-h water and chow exposure 
period. * - p<0.05; ns: no significant (ANOVA followed by Fisher’s test). 
 
3.4. Discussion 
The classical concept of OT’s involvement in the regulation of appetite revolves 
around the phenomena critical for maintaining and rescuing internal milieu. 
Indeed, OT signaling – especially within the hypothalamic-brainstem circuits -- 
aids in termination of eating behavior that poses threat to the water-electrolyte 
balance and to the functioning of the gastrointestinal tract, and that is associated 
with the ingestion of toxins [3, 4, 25]. The most recent discoveries have 
expanded upon this view as they strongly suggest that OT decreases appetite for 
carbohydrates and for palatable sweet tastants [26] by engaging a wider network 
of neural sites, including the VTA [9].  The current set of studies identifies for the 
first time the AcbC as a key site integrating OT’s involvement in energy 
homeostasis and feeding reward.  
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We found that AcbC injections of OT decreased hunger-derived intake of “bland” 
chow and the palatability-driven consumption of sweet solutions. In both cases, 
the effect was reversible by the pre-treatment with the OTr antagonist, L-
368,899, which suggests that the changes in feeding induced by AcbC OT are 
mediated by the OTr. The magnitude of the anorexigenic response in overnight-
deprived rats to AcbC OT was similar to those observed after lateral ventricular 
(e.g. [27]) and VMH [28] OT infusions and somewhat smaller than the reduction 
in feeding after OT administration into the fourth ventricle [29]. It supports the 
notion that while the hindbrain OTr has a critical role for the regulation of energy 
balance, the forebrain populations of this receptor, including in the AcbC, should 
be viewed as an important contributor to central mechanisms governing feeding 
for calories.  
One of the most crucial findings in research on OT’s influence on appetite in the 
recent years has been the set of discoveries linking OT and appetite for 
carbohydrates and for sweet taste.  OT neuronal activity is particularly high after 
consumption of a sucrose-rich meal [26]. Generalized knockout of the OT gene in 
mice results in the phenotype showing sweet and non-sweet carbohydrate and 
saccharin hyperphagia [30].  Peripheral infusions of the blood-brain barrier 
penetrant OTr antagonist, L-368,899, in wild-type mice promote intake of mono-, 
di- and polysaccharides and saccharin [10]. Those findings sparked the debate as 
to whether the aforementioned effects are particularly relevant to 
carbohydrates, to sweet taste or to hedonic processing. The latest data as well as 
the results presented herein point to a key role that OT plays in the regulation of 
the activity of the reward circuits, including of the AcbC. Carson et al reported 
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that systemic injection of OT decreases methamphetamine activation of the 
AcbC [31]. Baracz and colleagues found that pre-treatment with OT administered 
IP or directly into the AcbC attenuates the formation of a methamphetamine-
induced conditioned place preference [32]. The current experiments show 
reduced consumption of palatable sweet solutions in response to microinjections 
of OT in the AcbC at doses that were the same or lower than those reported for 
VTA administration of the peptide [9]. It should be emphasized that the observed 
change did not stem from altered thirst responsiveness as AcbC OT did not affect 
water intake in water-deprived rats. Notably, a significant decrease in saccharin 
solution intake was achieved with the OT dose that was ineffective in reducing 
the intake of chow or sucrose, which indicates that the presence of energy is not 
a sole factor in the regulatory mechanisms through which AcbC OT modifies 
consummatory behavior. This notion is strengthened by the outcome of the real-
time PCR experiments in which AcbC OTr transcript levels were affected by the 
caloric and non-caloric challenge, i.e., by both energy deprivation and exposure 
to palatable saccharin. This also seems in line with the growing body of evidence 
suggesting that the relationship between OT and suppression of appetite is 
independent from energy density of tastants, as OTr ligands modify intake of 
solid foods (such as chow or chocolate) as well as low-calorie fluids [26, 33, 34]. 
Accordingly, the AcbC OT signaling appears to represent the intertwined 
mechanisms of caloric and non-caloric feeding control. The AcbC OT-induced 
increase in overall c-Fos immunoreactivity in the PVN and SON as well as in the 
number of activated OT neurons is very much reminiscent of neuronal activity 
patterns associated with the end of a meal (regardless of whether palatable or 
“bland” food is offered) [26, 34]  and drug treatments that lead to early 
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termination of hunger- or reward-driven consumption [35, 36]. One should also 
note the fact that OT acting in the AcbC engages pathways that trigger activation 
of OT neurons in the hypothalamus. It suggests that AcbC OT might promote 
positive feedback within the accumbens-hypothalamic OT circuits, though it 
remains to be elucidated whether there is direct reciprocity between the AcbC-
PVN/SON OT pathway components or the effect is mediated via a wider network 
of sites.  
Many authors have reported changes in consumption after direct pharmacologic 
stimulation of the shell subdivision of the Acb. For example, gamma-
aminobutyric acid (GABA) A and GABA B ligands administered in the AcbSh 
modify a short-term feeding response to food deprivation [37]. Similarly, the 
blockade of AcbSh glutamate receptors and mu and kappa opioids receptor 
affects appetite [38], [39]. Importantly, our results add to the growing evidence 
suggesting that also the core subdivision of the Acb controls meal size after 
energy deprivation as well as in palatability-driven food intake. Aside from the 
OTr, the GLP-1 and opioid receptors are involved in AcbC feeding mechanisms 
[40, 41]. In fact, the change in feeding after the AcbC OT infusion with the lack of 
behavioral response to the AcbSh OT treatment resembles the effects of AcbC 
versus AcbSh GLP-1 injections [21]. Interestingly, just as OT, GLP-1 in the Acb 
affects processing of feeding-related and -unrelated rewards [40, 42, 43].  
While the results of our studies define AcbC OT signaling as crucial in energy- and 
reward-induced consumption, the CTA experiment did not show aversive 
consequences of the AcbC OT treatment. The lack of the learned avoidance 
response strongly suggests that the anorexigenic effects of OT do not stem from 
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undesirable sickness/malaise. It lends us confidence in classifying AcbC OT’s role 
as related to appetite regulation rather than to learning avoidance of potentially 
dangerous foods.  It should be noted that the reason behind assessing CTA 
effects of AcbC OT was not only to control for drug-induced illness, but also to 
examine whether the OTr in the AcbC might be physiologically involved in the 
development of taste aversions: It has been previously shown that OT is released 
in response to the presence of toxins, contributing to malaise-dependent 
anorexia [12], and that a systemic OTr antagonist treatment impairs acquisition 
of a CTA [44].  
For a number of reasons, including practicality of an experimental setup, the vast 
majority of feeding studies reported here and by other authors have been 
performed on animals housed individually. One should not forget though that 
food intake is oftentimes a social behavior, in which initiation, termination, 
dietary choices and meal duration, are influenced by the characteristics of the 
social environment. This particular issue needs to be considered especially in 
studies on neural systems that regulate both appetite and affiliative behaviors, 
including OT.  
OT facilitates pair bonding, mother-infant bonding, and social 
approach/recognition, and diminishes anxiety [45-49]. Peripheral and central OT 
release has been reported in response to positive social exposure [50]. 
Importantly, socially stimulated changes in Acb activity have been proposed to 
influence other concurrent physiological and behavioral parameters. For 
example, studies on the link between the Acb and drug abuse have shown that 
preference for cocaine can be modified by social interaction [51]. Lesions of the 
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AcbC induce preference for the social compartment in the CPP paradigm, 
whereas lesions of the AcbSh shift it towards the cocaine-associated chamber 
[52]. The results of the current study indicate that a social context has a 
profound effect on the ability of OT to affect feeding via the AcbC. Once the 
animal is placed in the environment in which social interaction occurs, intra-AcbC 
administration of OT does not diminish food intake driven by hunger or feeding 
induced by sweet flavor. While at present, it is extremely difficult to speculate on 
the exact nature of the observed phenomenon, it fits well with the previously 
reported findings showing that orexigenic effects of peripherally administered 
OTr antagonist in mice that were offered a meal in a social setting depended on 
the social status of animals [53]. Therefore, social cues appear to act as a 
modifying factor in the ability of OTr ligands to affect appetite. It is likely that in 
the case of a crosslink between social interactions and feeding, OT acts as a 
secretagogue of behavioral activity in response to complex cues. A similar 
hypothesis has been proposed in relation to OT facilitating a switch from food 
intake to affiliative or sexual behavior, thus balancing behaviors that contribute 
to internal homeostasis and evolutionary success [54, 55].  
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Chapter 4  
 
 
Is there a functional relationship between 
oxytocin and connexin 36 in the regulation of 
feeding? 
 
 
The data present in Chapter 2 and 3 of this thesis as well as the results reported 
by several laboratories indicate that central OT is involved in the regulation of 
three key aspects of food intake regulation: (a) it promotes termination of food 
intake upon consumption of high volume of food and associated increase in salt 
loading; (b) it decreases intake of palatable carbohydrates and sweet non-
carbohydrate, saccharin, thereby reducing feeding for reward; and (c) it brings 
on an immediate discontinuation of ingestive behavior when food is tainted with 
toxins (in the laboratory setting, this phenomenon is visualized through a 
conditioned taste aversion paradigm). 
These effects of OT are mediated by a widespread network of feeding-related 
brain sites that encompass areas classically viewed as involved in feeding for 
energy homeostasis (and homeostasis in general) and sites controlling 
consumption for reward. The hypothalamic – brainstem pathways largely 
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contribute to the homeostatic aspect of OT-driven regulation of appetite, 
preventing excessive distention of the stomach or abnormal plasma osmolality 
and promoting avoidance of foods whose ingestion might cause sickness/malaise 
[1]. On the other hand, the reward system – mainly the nucleus accumbens and 
ventral tegmental area – mediates OT’s inhibitory effects on the consumption of 
carbohydrates and non-carbohydrate sweet tastants, such as saccharin [1]. 
Importantly, as evidenced in the previous chapters of this thesis and Mullis et al. 
[2], the role of the aforementioned sites in particular aspects of feeding control is 
not rigid: for example, the Acb injections of OT decrease both feeding for reward 
and deprivation-induced intake of “bland” yet energy-dense chow; and 
generalized injections of OTr antagonists increase intake of palatable tastants 
(Chapter 2 and [3]). 
The quest for a better understanding of the nature of OT’s involvement in 
feeding regulation has led me to explore a question of whether OT would still 
affect the key aspects of food intake in a unique animal model characterized by a 
combined dysregulation of feeding for energy, feeding for reward, and avoidance 
of toxic foods.  
Therefore, in Part A of this chapter (Section 4.1), I present the ingestive 
behavior characterization of a novel knockout (KO) mouse strain that does not 
express a key gap junction protein, connexin 36 (Cx36) and – consequently – 
shows aberrant intake of energy-dense “bland” food, decreased intake of 
palatable tastants and hypersensitivity to aversive stimulation. It should be 
emphasized that Cx36 is ubiquitous in the reward system as well as in the 
hypothalamus and brain stem – hence, all areas through which OT exerts its 
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action on homeostatic and reward-driven feeding. Properly functioning gap 
junctions ensure integrity of the neural circuit by providing a means of 
communication between adjacent neurons. Therefore, I hypothesize that - in the 
Cx36-deficient feeding-related brain networks in the Cx36 KO mouse - OT might 
show diminished effectiveness in modifying most relevant aspects of food intake. 
This functional relationship between OT and Cx36 in the feeding context is 
explored in Part B of this chapter (Section 4.2). 
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4.1. (PART A) Connexin 36 KO mice show overconsumption 
of high-energy “bland” food, diminished sensitivity to 
feeding reward and excessive taste aversions. 
Abstract 
Connexin 36 (Cx36) is a gap junction molecule ubiquitously expressed in central 
areas that govern energy homeostasis, reward and food aversions. It has been 
shown that Cx36 deletion is associated with dysregulation of GABA and 
dopamine in reward pathways and with decreased ethanol intake in Cx36 
knockout (KO) mice. Here, we used the Cx36 KO model to investigate whether 
the lack of Cx36 affects key specific aspects of food intake control: eating for 
energy, eating for pleasure, and food avoidance resulting from an association 
between consumption of a given tastant and subsequent gastrointestinal 
sickness. To study an association between Cx36 and homeostatic control of 
feeding, we determined intake of standard chow in ad libitum-fed Cx36 KO 
versus WT mice as well as a magnitude of a conditioned taste aversion (CTA) 
response to lithium chloride (LiCl). A potential relationship with feeding reward 
was studied by assessing intake of palatable sweet and fatty tastants in WT vs 
Cx36 KO mice, by examining expression profile of opioid system genes involved 
in feeding reward, and sensitivity of Cx36 KOs to feeding reward modifying 
opioid ligands, naltrexone and butorphanol. Cx36 KOs showed increased intake 
of energy-dense “bland” chow and decreased consumption of sweet and fatty 
palatable solutions offered episodically and in an unrestricted manner. Cx36-
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deficient mice maintained on a regular diet displayed an altered baseline 
expression profile of opioid system genes in the hypothalamus and nucleus 
accumbens. Cx36 KOs exhibited a diminished sensitivity to consumption 
modifying properties of naltrexone and butorphanol (sucrose) or a lack thereof 
(saccharin). Finally, Cx36 KOs developed taste aversions even after 
administration of LiCl at a dose that was subthreshold in the WTs. Overall, the 
data indicate that Cx36 is involved in the “homeostatic” (energy intake and 
aversions) and “non-homeostatic (reward) mechanisms governing appetite. Its 
absence shifts the threat-pleasure continuum by reducing feeding reward and 
promoting hypersensitivity to negative stimuli associated with a meal. It supports 
ingestion of highly caloric, “bland” and “safe” foods.   
4.1.1. Introduction 
Gap junctions (GJs), pores formed by connexin (Cx) subunits, provide a means for 
intercellular communication in the brain [4]. The passage of molecules through 
neuronal GJs coordinates cell firing, and metabolic as well as transcriptional 
events between coupled neurons. Compared to chemical synapses, GJ electrical 
synapses synchronize outputs of coupled neurons and allow ultra-fast spread of 
information.  
Thus far, 20 connexin genes have been defined [5]. Among the two types of Cxs 
most ubiquitously expressed in mammalian neurons, only Cx36 is prevalent in 
the mature CNS [6]. Cx36 positive neurons have been demonstrated in a number 
of brain areas involved in cognition, learning, memory and emotion-related 
processing, including the hippocampus, cerebral and piriform cortex, amygdala, 
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mesencephalon, and thalamus [6]. Cx36 has been shown to facilitate plasticity 
[7], promote glutamate-mediated cell death post-injury [8], affect motor 
learning [9, 10] mediate sensitivity to anesthetic drugs [11, 12], and affect 
learning- and anxiety-related parameters [13]. 
From the standpoint of food intake regulation, it is extremely important that 
Cx36 is abundantly expressed in the vast network of central sites affecting 
appetite, especially the mesolimbic reward system, hypothalamus, and various 
brain stem nuclei [6]. Cx36 has been shown to be co-expressed in corticotropin 
releasing hormone (CRH) neurons, which are part of the brainstem-hypothalamic 
pathways regulating feeding for energy and participating in the generation of 
emetic responses [14]. A relationship between Cx36 and reward has been 
underscored by comprehensive electrophysiological studies that established the 
role of Cx36 in the generation of high-frequency oscillations and synchrony [15], 
particularly within GABA and dopamine (DA) circuits [16-19]. Behavioral 
experiments have brought a groundbreaking discovery that Cx36 knockout (KO) 
mice are less prone to drinking alcohol. The loss of Cx36-dependent electrical 
coupling within the key reward pathway component, the ventral tegmental area 
(VTA), leads to the dyssynchrony of the GABA system resulting in disinhibition of 
DA neurons (hyper-DA state), and consequently decreases the hedonic value of 
ethanol intake [19].  
Surprisingly, despite evidence suggesting a potential link between Cx36 and 
appetite, thus far, this issue has not been investigated in detail. Therefore, in the 
current set of studies, we used the Cx36 KO mouse model to investigate whether 
the lack of Cx36 affects key specific aspects of food intake control: eating for 
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energy, eating for pleasure, and food avoidance resulting from an association 
between consumption of a given tastant and subsequent gastrointestinal 
sickness. The regulation of calorie consumption as well as avoidance of 
potentially toxic foods can be viewed as “homeostatic” control of appetite, 
whereas eating for pleasant taste is driven by the rewarding component of 
gustatory mechanisms. First, in order to establish energy-driven appetite in the 
absence of Cx36, we measured consumption of standard chow in ad libitum-fed 
Cx36 KO versus WT mice. Then, in order to determine whether there is a link 
between Cx36 and feeding reward, we measured the consumption of sweet and 
lipid solutions in episodic and unrestricted access paradigms in Cx36 KO versus 
WT mice and substantiated our findings by using a pharmacological blocker of 
Cx36 gap junctions, quinine, in WT animals. As the consumption of palatable 
tastants was lower in the KO animals, we hypothesized that the genetic deletion 
of Cx36 affects baseline expression of opioid system-related genes, which are the 
key components of central mechanisms governing feeding for pleasure [20] 
thereby diminishing KO animals’ sensitivity to feeding reward. Hence opioid 
transcript levels were assessed with real-time PCR in the hypothalamus and Acb 
of Cx36 KOs and their background strain. Finally, we tested sensitivity of Cx36 
KOs versus WTs to feeding inhibitory properties of an opioid receptor antagonist, 
naltrexone, and feeding stimulatory properties of an agonist, butorphanol, on 
sugar and saccharin solution intake. Finally, in order to examine whether Cx36 
status affects aversive responsiveness, we injected Cx36 KO and WT mice with 
the same low dose of malaise inducing toxin, LiCl, and determined whether the 
magnitude of a conditioned taste aversion (CTA) differs between the genotypes. 
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4.1.2. Materials and Methods 
4.1.2.1. Animals 
The Cx36 KO model, developed and kindly provided to our laboratories by Prof. 
David Paul [21], has been used by us and others in earlier studies [22], [23]. Male 
homozygous Cx36 KO and WT littermates (C57/B6-129SvEv mixed 
background) were individually housed in conventional cages with a 12:12 LD 
photoperiod (lights on at 0700) in a temperature-controlled room (21°C). Age-
matched animals weighed ca. 26 g ± 3 at the beginning of the studies (there was 
no difference in b. wt. between the genotypes). Mice had unlimited access to tap 
water and standard rodent chow (Teklad Global Diet 2018) throughout the 
studies unless noted otherwise. The procedures described herein were approved 
by the University of Waikato animal ethics committee. 
4.1.2.1.1. Energy-driven intake of standard chow in Cx36vKO vs WT mice 
Age-matched Cx36 KO and WT male mice (n=8/genotype; there is no difference 
in body weight between the strains: 26 g ± 3) had intake of regular (“bland”) 
chow and water measured every 24 h for 3 days. The animal had not been 
exposed to other non-standard tastants. The amounts of chow and water 
consumed were calculated per kg of body weight and the means ± SEM were 
established for each genotype. A Student’s t-test was used to establish the 
difference in consumption between WT and Cx36 KO mice (significant when 
p≤0.05). 
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4.1.2.1.2. Episodic intake of palatable tastant solutions in Cx36 KO vs WT mice 
In a series of experiments, we tested the intake of 0.1% saccharin, 5% sucrose, 5% 
glucose, 5% fructose or 4.1% Intralipid (Fresenius, Sweden) solutions in a single-
bottle no-choice paradigm. Cx36 KO and WT mice (n=13-18/tastant) had been 
pre-exposed to the respective solutions 2 h/day (10:00–12:00) for 5 days. Chow 
and water were removed from the cages for the 2-h period of palatable tastant 
presentation. The animals were then given a single bottle containing a palatable 
tastant. The amount of the solution consumed was calculated and the means 
were reported in g/kg of b. wt. A Student’s t-test was used to assess differences 
in consumption for each of the palatable solutions between WT and KO animals 
(significant when p≤0.05). 
As a control study for the ability of Cx36 gap junctions to affect episodic 
consumption of palatable tastants, we subjected the WT mice to a similar 
paradigm of saccharin solution availability as described above, injected them 
with saline or 30 mg/kg b. wt quinine (Cx36 gap junction blocker) 5 minutes 
before palatable tastant presentation and determined saccharin solution intake 
in the 2-h test period. The dose of quinine was selected based on previous 
studies showing antinociceptive and antiepileptic effects of the compound [24], 
[25]. The amount of consumed saccharin solution was expressed in g/kg b. wt. 
and the data of saline vs. quinine groups compared with a t-test (significant 
when p≤0.05). 
4.1.2.1.3. Unrestricted intake of palatable solutions in Cx36vKO vs WT mice 
We assessed the intake of 0.1% saccharin, 5% sucrose, 5% glucose, 5% fructose 
or 4.1% Intralipid when each of these tastants was available ad libitum (along 
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with standard chow and water) for 3 consecutive days. KO and WT mice were 
given a single bottle containing a palatable tastant for 3 days (n=8/WT and n=8 
KO for each tastant). The amount of the tastants and chow consumed on Day 2 
and 3 (data from Day 1 were not included in the analysis to discount the 
potential effect of novelty) was calculated and the means were reported in g/kg 
of b. wt. A Student’s t-test was used to establish the difference between WT and 
Cx36 KO consumption in consumption (significant when p≤0.05). 
4.1.2.2. Baseline expression of opioid system genes in the 
hypothalamus and Acb in Cx36 KO vs. WT mice 
Wt and Cx36 KO mice (n=8/group), maintained on ad libitum access to standard 
chow and water, were decapitated (10:00-11:00) and the hypothalamus and Acb 
were collected according to the Paxinos and Watson brain atlas. The tissue was 
placed in RNAlater at room temperature for 2h and then stored at -80°C. RNA 
was extracted by the Quick-RNATMkits (Zymo Research) and the absence of DNA 
was confirmed by PCR. Total RNA concentration was measured with Nanodrop 
2000 (Thermo Scientific). For cDNA synthesis, 9 μl of RNA was reverse-
transcribed in a final volume of 20 μl containing 10 μl 2X RT Reaction Solution 
and 1 μl Enzyme Mix (HiSenScriptTM RH(-) cDNA Synthesis Kit, iNtRON 
Biotechnology). The reaction was performed for 1h at 42°C, followed by 5 min at 
85°C and 5 min at 4°C, and the presence of cDNA was confirmed by PCR. Each 
rtPCR, with a total volume of 20 μl, contained 8 μl template cDNA, 2μl Primers 
Mix (Forward and Reverse primers) and 10 μl of 2X RealMODTM GH Green Real-
time PCR Master Mix (Master Mix Kit, iNtRON). rtPCRs were done in duplicates, 
and negative controls were included on each plate. Amplification was performed 
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as follows: denaturation at 94°C for 5 min, 50 cycles of denaturation at 94°C for 
10 s, annealing for 15 s, and extension at 62°C for 30 s.  Three housekeeping 
genes were analyzed (Table 4.1). A Rotor-Gene SYBR Green PCR (QIAGEN) was 
used. Data analyses have been performed by Rotor-Gene 6000 software 
1.7 (QIAGEN). Primer efficiencies of 11 genes (Table 4.1) were calculated and 
samples were corrected for differences in efficiencies. The Pfaffl equation [26] 
[27] was used to calculate normalization factors based on housekeeping gene 
expression. Differences in gene expression between groups were analyzed using 
a t-test (different when p≤0.05).  
4.1.2.3. Effect of opioid receptor agonist and antagonist on 
consumption of sweet palatable tastants in Cx36 KO vs. WT mice 
Several days prior to the beginning of the experiments, Cx36 KO and WT mice 
had been pre-exposed to 0.1% saccharin or 10% sucrose solutions for 24 h to 
prevent neophobia. Similar to the episodic exposure experiments described 
above (section 4.1.2.1.2), animals (n=7-10/group) were accustomed to having 
access to either 0.1% saccharin or 10% sucrose for 2 h/day (1000–1200 h). 
Standard food and water were removed for the 2-h period of palatable tastant 
presentation. Five min prior to palatable solution exposure, mice were injected 
IP with (a) saline or 0.03, 0.1, 0.3, 1 and 3 mg/kg b. wt. of naltrexone or (b) saline 
or 0.1, 0.3, 1 and 3 mg/kg b. wt. of butorphanol tartrate. The amount of the 
palatable tastant consumed during the 2-h period was calculated in g/kg of b. wt. 
One-way ANOVA followed by Fisher’s post-hoc test was used to establish 
effective doses of naltrexone and butorphanol in saccharin and sucrose 
consumption for the Cx36 KO and WT strains (different when p≤0.05).  
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Table 4.1.1 Forward and reverse real-time PCR primer sequences. 
 
4.1.2.4. Effect of lack of Cx36 on acquisition of LiCl-induced CTA 
We used a standard CTA protocol in which Wt and KoCx36 mice were 
accustomed to having access to water for 1 h per day (11:00–13:00, 2d). 
Standard chow was removed from hoppers for the 1-h period of scheduled fluid 
presentation. On day 3, mice were given a novel flavored drink (pineapple juice, 
Golden Circle, Australia; composition: per 100ml, Energy 219kJ, Total carbs 12.2g, 
Sugars 10.6g) instead of water for sixty minutes and immediately after the end of 
the drinking session they received an IP injection of LiCl (Sigma; 0.6 mEq/kg b. 
wt.) or saline (n=8/group). On day 4, a standard two-bottle preference test 
(flavored solution versus water) was used to assess acquisition of a CTA in Wt vs 
KoCX36 mice. Bottles were weighed and percentages of the juice solution intake 
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(out of cumulative, i.e. sweetened solution plus water, intakes) were calculated. 
A difference in consumption between groups was calculated using a one-way 
ANOVA followed by Fisher’s post-hoc test. A Student’s t-test was used to 
establish the difference consumption between two groups (significant when 
p≤0.05). 
4.1.3. Results 
Mice lacking the functional Cx36 gene showed elevated intake of energy-dense 
regular (“bland”) chow in an ad libitum feeding paradigm. Adult (age-matched), 
same-weight Cx36 KOs ate more energy-dense chow over a 24-h period 
(p=0.0001) than their WT counterparts (Figure 4.1.1).  
On the other hand, the KO animals drank significantly less of the sweet palatable 
solutions and lipid emulsion (saccharin, p=0.008; sucrose, p=0.009; glucose, 
p=1E-5; fructose, p=0.0003, Intralipid, p=0.002) offered in a brief 2-h session 
(with no chow or water available during that time; Figure 4.1.2A). A similarly 
diminished intake of the palatable tastants was observed when saccharin (p=0.02) 
sucrose (p=2E-6), glucose (p=2E-6), fructose (p=2E-7) and Intralipid (p=0.0002) 
were given in an unrestricted manner for 48 h (chow/water available ad libitum; 
Figure 4.1.2B). Importantly, water intake did not differ between KO and WT mice 
(p=0.23).  
Cx36 blocker, quinine, administrated IP just before the 1-h period of exposure to 
the saccharin solution in WT mice, significantly decreased the intake of this 
sweet tastant (p=0.004; Figure 4.1.2C). 
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In the PCR studies, we found that baseline expression of opioid system genes 
differs in Cx36KO vs WT mice maintained on a standard diet (Figure 4.1.3). The 
KOs showed decreased mRNA levels of KOR (p=1E-06), MOR (p=5E-08), PNOC 
(p=0.0005), ORPL1 (p=6E-05), and increased DYN mRNA content (p=1E-05) in the 
hypothalamus, whereas PENK transcript expression was higher (p=0.03) in the 
nucleus accumbens.  
 
NTX or butorphanol injections in animals given access to saccharin or sucrose, 
produced different dose-response profiles in Cx36 vs WT mice (saccharin: ANOVA 
F=6  p=2E-4, sucrose ANOVA:F=4 p=0.02) (Figure 4.1.4). While the 0.1-mg and 
0.3-mg doses of NTX decreased sucrose consumption in WTs (p=0.02 and p=0.01, 
respectively), 3 mg NTX had to be used to generate a reduction in sucrose intake 
in KOs (p=0.007:). NTX at 1 mg (p=0.008) decreased saccharin intake in WT 
animals, but even the 3-mg dose was ineffective in the KO strain (p=0.6).  
Conversely, butorphanol increased sucrose consumption at 0.3 mg (p=0.02); and 
1 mg (p=0.004) in WTs, whereas 3 mg (p=0.01) was the lowest effective dose in 
Kos (ANOVA: F= 6.5 p= 2E-4)(Figure 4.1.4C). Saccharin consumption increased 
after injection of 0.3 and 1 mg butorphanol in WT mice (p=0.004 and p=0.004, 
respectively ANOVA F= 11.8 p<1E-4) but it remained unchanged even after the 3-
mg butorphanol treatment (Figure 4.1. 4).  
LiCl injected at a 0.6 mEq/kg dose was not sufficient to induce a conditioned 
taste aversion in WT mice: LiCl- and saline-treated WTs showed similar 
preference for the flavored solution. On the other hand, LiCl at the same dose 
induced a robust aversive response in Cx36 KO mice (p=8E-5, ANOVA F=13 
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p=1.7E-7) as their flavored solution intake on the subsequent presentation in a 
two-bottle test was decreased by 70% (Figure 4.1.5) 
 
Figure 4.1.1: Connexin 36 knockout (Cx36 KO) mice consume more regular chow in an 
unrestricted 24-h access paradigm, compared to wild-type (WT) controls. *** - p≤0.001. 
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Figure 4.1.2: Connexin 36 knockout (Cx36 KO) mice consume smaller amounts of 
palatable solutions offered (A) episodically for 2 h or (B) in an unrestricted 48-h access 
paradigm, compared to wild-type (WT) controls. A peripheral injection of a 
pharmacological blocker of Cx36 gap junctions, quinine, reduces saccharin solution 
intake (C). * - p≤0.05; ** - p≤0.01; *** - p≤0.001. 
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Figure 4.1.3: Connexin 36 knockout (Cx36 KO) mice having unrestricted access to 
standard food and water display a different baseline mRNA expression profile of select 
opioid system genes than wild-type (WT) controls. Gene expression levels in the 
hypothalamus and nucleus accumbens were measured with real-time PCR. KOR, kappa 
opioid receptor; MOR, mu opioid receptor; PNOC, pronociceptin; ORPL1, 
nociceptin/orphanin FQ receptor; PENK, proenkephalin; POMC, proopiomelanocortin. * 
- p≤0.05; ** - p≤0.01; *** - p≤0.001. 
 
 
Figure 4.14: Effects of naltrexone (top: A, B) and butorphanol tartrate (bottom: C, D) on 
the intake of sucrose (A,C) and saccharin (B, D) solutions offered for 2 h to connexin 36 
knockout (Cx36 KO) and wild-type (WT) mice. Doses of naltrexone and butorphanol 
represent mg/kg b. wt. injected intraperitoneally. * - p≤0.05; ** - p≤0.01; *** - p≤0.001. 
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Figure 4.1.5: A CTA response after injection of the same 0.6 mEq dose of LiCl in Cx36 KO 
vs WT mice. The graph shows relative (%) intake of a flavored solution offered in a two-
bottle choice test in water-deprived animals (water was the control fluid in the two-
bottle test).*** - p≤0.001. 
 
4.1.4. Discussion 
A dynamic balance between numerous mechanisms that govern appetite 
determines the overall energy consumption, proper macro- and micronutrient 
intake, as well as avoidance of those foods that – despite their attractive taste or 
energy content – may provoke unpleasant gastrointestinal sensations [28, 29]. A 
dysregulation of this intricate system may cause most profound metabolic and 
energy balance consequences for the organism by, for example, inducing 
excessive intake of highly palatable tastants, shifting the drive to eat away from 
foods that bring energy to those of low nutritional yet high gustatory value, and 
failing to prevent intake of toxic ingestants [30]. The current set of studies shows 
that Cx36 is critical in central processing of energy homeostasis, reward and 
aversion, thus, it appears to be part of the molecular mechanisms that serve as 
the broad foundation of appetite control. 
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The mesolimbic reward pathways as well as reward-related molecules scattered 
throughout the widespread network of sites that govern food intake and energy 
metabolism, promote overconsumption of tasty foods [31, 32]. Cx36, as a key 
molecular component of gap junctions in the adult CNS, serves a critical role in 
ensuring functional integrity of brain circuits, including those involved in reward 
[6, 19]. It has been previously shown that silencing Cx36 expression leads to a 
disruption of GABA and DA signaling [16-19]. Genetic deletion of Cx36 has also 
been found to decrease ethanol consumption in mice [19]. The current set of 
data shows that Cx36 gene knockout and the pharmacological blockade of Cx36 
GJs diminish intake of palatable solutions in mice. The dysregulation of the 
opioid system - a consequence of impaired Cx36 GJ coupling - likely underlies this 
reduced drive to eat for pleasure. 
Animals typically prefer sweet and fatty foods, and they ingest large quantities of 
solid and liquid diets that contain sugars, non-carbohydrate sweeteners, and/or 
fats, regardless of overall caloric density of such diets [33, 34]. Importantly, 
reward-driven consumption of solid and liquid diets occurs regardless of the fact 
whether the animal has or has not been food- or water-deprived [35, 36]. Non-
deprived Cx36 KO mice did consume the palatable liquid diets given episodically 
and in an unrestricted manner, which suggests that these solutions are not 
completely devoid of hedonic value to these animals. However, each of the 
palatable tastants was consumed less avidly by the KOs compared to their WT 
counterparts, indicating that the processing of rewarding aspects of consumption 
of these liquid diets was impaired in the Cx36-deficient mice. That water intake 
does not differ between KOs and WTs makes it unlikely that the effect was cause 
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by differences in thirst responsiveness. The fact that KOs ingests less of the non-
caloric saccharin solution than WT controls rules out a scenario in which 
diminished energy needs are the culprit underlying lower intake of palatable 
tastants. It should also be noted that the feeding reward experiments presented 
herein employed a wide variety of tastants that engage different subsets of taste 
receptors; therefore, along with the previously reported data on the relationship 
between Cx36 and alcohol-derived reward [19], our results imply that aberrant 
processing of reward in Cx36 KOs expands upon feeding for pleasant taste. At the 
same time, it should be noted that while genetic deletion of Cx36 led to a 
reduction of feeding for palatability, it was associated with a higher baseline 
level of “bland” chow consumption.  It should be emphasized that the more avid 
intake or regular chow in the KOs did not result in differences in body weight 
between the two genotypes, which suggests that metabolic and/or absorptive 
processes might be affected by Cx36 knockout. Importantly, regardless of the 
nature of energy conversion efficiency, KO animals’ enhanced appetite for high-
energy foods indicates a change in feeding control that promotes an increase in 
energy consumption.                                                                                                                                                                                                                                              
Interestingly, administration of quinine in non-deprived WT mice just prior to 
their gaining brief episodic access to the saccharin solution generated a decrease 
in saccharin intake. The parallel effects of gene deletion and pharmacological 
blockade of the GJ molecule lend us more confidence in defining Cx36 as being 
involved in feeding reward. Overall, changes in reward processing are evoked not 
just by a constitutive absence of the Cx36 gene, but also by using a transient 
Cx36 blocker; hence they can be dependent on acute changes in the Cx36 GJ 
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functional status as well as on long-term molecular changes associated with the 
lack of Cx36. 
It has been previously reported that Cx36 deficiency in the KO model leads to 
significant abnormalities in DA and GABA signaling within the VTA-accumbens 
pathways, thereby contributing to the impaired processing of rewarding 
stimulation [16-19]. Our real-time PCR data suggest that changes in the 
molecular content of reward-related circuits are even more profound as the 
baseline expression profile of genes that give rise to select opioid peptides and 
receptors is greatly affected. The key role of endogenous opioids in palatability-
induced consumption has been shown beyond reasonable doubt. It is well known 
that opioid receptor agonists induce intake of preferred tastants, while 
antagonists are effective in decreasing intake of tasty foods [37, 38]. 
Modifications in access to palatable diets affect opioid peptide/receptor mRNA 
and protein levels [39-41], whereas constitutive and conditional changes in 
expression of opioid system genes are associated with an altered drive to ingest 
rewarding tastants [42-44]. That Cx36 KO animals maintained on standard “bland” 
chow show different levels of opioid mRNAs indicates that - already at the 
baseline behavioral state - there is an atypical expression of genes related to 
feeding reward, most likely being one of the underlying factors in aberrant 
processing of palatability in Cx36 KOs. It should be noted that opioid system 
mRNA levels were changed not only in the nucleus accumbens, which is intuitive 
taking into account its role in reward, but predominantly in the hypothalamus, 
where the receptor transcripts were greatly affected. While numerous 
intraparenchymal injection studies have shown that opioid receptors in the 
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hypothalamus modify palatability-driven feeding [45], they are also though to 
couple reward system’s activity with the homeostatic and neuroendocrine 
responses of the hypothalamus [37, 46] . 
The real-time PCR findings showing an altered expression profile of opioid-
related genes are further substantiated by the studies utilizing injections of 
opioid receptor ligands that are known to stimulate (butorphanol) or reduce 
(naltrexone) consumption of palatable tastants [37, 38]. We found that WT mice 
offered either sucrose or saccharin exhibited a typical orexigenic response to 
butorphanol and hypophagia after naltrexone treatment. On the other hand, 
Cx36 KOs exhibited a diminished sensitivity to consumption modifying properties 
of each of the opioid ligands (sucrose) or a lack thereof (saccharin). While it is 
difficult to speculate whether the marked shifts in the dose-response curves can 
be directly attributed to changes in opioid system’s expression profile or rather 
to impaired coupling of reward signaling due to DA and GABA disruption (or 
both), it is clear that Cx36 deletion leads to gross abnormalities in the molecular 
content, sensitivity and functioning of reward circuits. 
Finally, our taste aversion experiments show that Cx36 KO mice exhibit a greater 
level of sensitivity to unpleasant consequences of LiCl injection. While 
administration of 0.6 mEq/kg LiCl in WT mice did not produce a CTA, the same 
dose of the toxin caused a profound CTA in the KOs. Hence, the Cx36 molecule 
participates also in central processing of stimuli that bring on a challenge to 
internal milieu. The loss of the Cx36 protein translates into hypersensitivity to 
aversions, which poses a potential threat for the animal in that it would become 
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too selective in search for “safe” foods or would avoid tastants even after very 
benign negative outcomes of consumption.  
Overall, the data indicate that Cx36 is involved in the “homeostatic” (energy 
intake and aversions) and “non-homeostatic (reward) mechanisms governing 
appetite. Its absence shifts the threat-pleasure continuum of food intake by 
reducing the rewarding component of eating behavior and promoting 
abnormally high sensitivity to negative stimuli associated with a meal. It also 
supports ingestion of highly caloric, “bland” and “safe” foods.   
 
 
 
  
146 
 
4.2. (PART B) Functional relationship between oxytocin and 
connexin 36: a preliminary report 
Abstract 
Connexin 36 (Cx36) is a gap junction molecule expressed in feeding-related 
neural circuits. The Cx36 knockout (KO) mouse is a unique model that 
encompasses dysregulation of three major aspects of food intake: eating for 
energy, for pleasure, and hypophagia in response to toxins. Interestingly, 
anorexigenic neuropeptide oxytocin (OT) also regulates the three aspects of 
feeding. As the OT peptide/receptor and Cx36 are coexpressed in feeding 
networks, OT and Cx36 may be part of common pathways governing appetite. 
We hypothesized that the presumed OT-Cx36 functional relationship might be 
reflected by the altered ability of OT to exert its action in brain circuits devoid of 
Cx36. Effectiveness of injections of OTr ligands, changes in OT gene expression 
and in OT neuronal activation in Cx36 KOs were determined in the three aspects 
of consumption. Cx36 KO mice ingest more energy (standard chow) than WTs, 
and we found that this enhanced appetite for calorie-dense food is associated 
with changed expression of OT and OTr genes (qPCR). Cx36 KOs exhibit increased 
sensitivity to taste aversion inducing chemical stimuli. We showed that this is 
associated with a higher number of Fos-positive OT neurons activated by toxin 
(LiCl). Finally, to study the link between Cx36 and OT in feeding reward, we 
injected KO mice with an OT antagonist, L-368,899 and determined that Cx36 
deletion impairs effectiveness of OTr blockade on consumption driven by sweet 
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taste. Overall, the data suggest that Cx36 is a key component of feeding-related 
circuits through which OT executes its functions.  
4.2.1. Introduction 
The connexin 36 knockout (Cx36 KO) mouse is a unique model that encompasses 
dysregulation of three major aspects of food intake control: eating for energy, 
eating for pleasant taste, and eating in situations when homeostasis can 
potentially be jeopardized by ingesting tainted foods. Cx36 KO mice show 
increased “bland” chow intake and decreased intake of palatable solutions (both 
sweet and fat).  Furthermore, these mice are prone to developing conditioned 
taste aversions (CTA) even when food exposure is paired with low doses of LiCl, a 
toxin that causes unpleasant gastrointestinal sensations, that are not effective in 
wild-type (WT) control animals.  
Oxytocin (OT) has been hypothesized to play a significant role in all three of the 
aforementioned aspects of feeding. OT neurons are thought to promote 
satiation-driven termination of food intake, a decrease in palatability-dependent 
consumption and – finally – an immediate discontinuation of consummatory 
behavior once the presence of toxins is recognized by the chemoreceptor 
neurons localized in the area postrema (AP). Importantly, studies in laboratory 
animals have shown the presence of gap junctions in the paraventricular (PVN) 
and supraoptic (SON) nuclei of the hypothalamus, where OT perikarya are 
amassed [14, 47, 48]. Some (but not all – [14]) authors have provided evidence 
that Cx36-containing gap junctions exist between hypothalamic OT cells [47, 
49].  Therefore, both OT and Cx36 may be molecular substrates of common 
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neural pathways that govern appetite, and this presumed functional relationship 
– if it indeed takes place - might affect the ability of OT to exert its action in 
circuits that have to rely on gap junctions devoid of Cx36. 
The aim of these experiments was to examine whether there is a functional 
relationship between OT and Cx36 in the regulation of food intake. The Cx36 KO 
mouse was used as a Cx36-null animal model that displays aberrant energy 
intake, reward-driven feeding and taste aversions. Effectiveness of injections of 
OTr ligands, changes in OT gene expression and in OT neuronal activation in the 
Cx36 KO animal were determined in key paradigms associated with each of the 
three aspects of consummatory behavior. Since Cx36 KO mice eat on average 
more standard (“bland”) chow than WT controls, we determined whether this 
enhanced appetite for food is associated with different levels of expression of 
the OT gene (established with real-time PCR) in the hypothalamus and nucleus 
accumbens. A difference in OT gene expression could predispose the KOs to 
consuming more energy (thus, having delayed satiety). In order to study the link 
between Cx36 and OT in the feeding reward context, we injected KO mice with a 
BBB penetrant OTr antagonist, L-368,899 [50] to examine whether the Cx36-null 
status impairs effectiveness of OTr blockade on consumption driven by sweet 
taste. Finally, we investigated whether the enhanced CTA responsiveness of Cx36 
KO mice is associated with a greater level of OT neuronal activity. Neuronal 
activation was established by using double immunohistochemistry for c-Fos (an 
immediate-early gene product) and OT.  
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4.2.2. Materials and Methods 
4.2.2.1. Animals  
Male Cx36 KO and WT littermates (C57/B6-129SvEv mixed background) were 
individually housed in conventional cages with a 12:12 LD photoperiod (lights on 
at 0700) in a temperature-controlled room (21°C). Age-matched animals weighed 
ca. 26 g ± 3 at the beginning of the studies (there was no difference in b. wt. 
between the genotypes). Mice have unlimited access to tap water and standard 
rodent chow (Teklad Global Diet 2018) throughout the studies unless noted 
otherwise. The procedures described herein were approved by the University of 
Waikato animal ethics committee. 
4.2.2.2. Baseline expression of OT and OTr genes in the 
hypothalamus and Acb in Cx36 KO vs. WT mice 
Wt and Cx36 KO mice (n=8/group), maintained on ad libitum access to standard 
chow and water, were decapitated (10:00-11:00) and the hypothalamus and Acb 
were collected according to the Paxinos and Watson brain atlas. The tissue was 
placed in RNAlater at room temperature for 2h and then stored at -80°C. RNA 
was extracted by the Quick-RNATMkits (Zymo Research) and the absence of DNA 
was confirmed by PCR. Total RNA concentration was measured with Nanodrop 
2000 (Thermo Scientific). For cDNA synthesis, 9 μl of RNA was reverse-
transcribed in a final volume of 20 μl containing 10 μl 2X RT Reaction Solution 
and 1 μl Enzyme Mix (HiSenScriptTM RH(-) cDNA Synthesis Kit, iNtRON 
Biotechnology). The reaction was performed for 1h at 42°C, followed by 5 min at 
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85°C and 5 min at 4°C, and the presence of cDNA was confirmed by PCR. Each 
rtPCR, with a total volume of 20 μl, contained 8 μl template cDNA, 2μl Primers 
Mix (Forward and Reverse primers) and 10 μl of 2X RealMODTM GH Green Real-
time PCR Master Mix (Master Mix Kit, iNtRON). rtPCRs were done in duplicates, 
and negative controls were included on each plate. Amplification was performed 
as follows: denaturation at 94°C for 5 min, 50 cycles of denaturation at 94°C for 
10 s, annealing for 15 s, and extension at 62°C for 30 s.  Three housekeeping 
genes were analyzed (Table 1). A Rotor-Gene SYBR Green PCR (QIAGEN) was 
used. Data analyses have been performed by Rotor-Gene 6000 software 
1.7 (QIAGEN). Primer efficiencies of 2 genes (Table 1) were calculated and 
samples were corrected for differences in efficiencies. The Pfaffl equation [26] 
was used to calculate normalization factors based on housekeeping gene 
expression. Differences in gene expression between groups were analyzed using 
a t-test (different when P≤0.05). 
 
Table 4.2.1. Real-time PCR primers (all supplied by Integrated DNA Technologies). 
 
Eating behavior genes     
 FORWARD REVERSE 
OXT CCT ACA GCG GAT CTC AGA CTG A TCA GAG CCA GTA AGC CAA GCA 
OXTR TCT TCT TCG TGC AGA TGT GG CCT TCA GGT ACC GAG CAG AG 
 
Housekeeping genes     
 FORWARD REVERSE 
B actin TGG CAC CAC ACC TTC TAC AAT GAG  GGG TCA TCT TTT CAC GGT TGG 
Atp5b GGC ACA ATG CAG GAA AGG TCA GCA GGC ACA TAG ATA GCC 
B tub CGG AAG GAG GCG GAG AGC AGG GTG CCC ATG CCA GAG C 
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4.2.2.3. Effect of OTr blockade on episodic intake of palatable 
tastant solutions in Cx36 KO mice. 
Cx36 KO mice were pre-exposed to palatable sweet tastants for 24 hours. 
Animals (n=7) were accustomed to having access to 0.1% saccharin, 10% sucrose,  
10% glucose or 10% fructose, given alone, for 1 h (1100–1200 h) per day for 1 
day. Chow and water were removed from the cages for the 1h period of 
palatable tastant presentation. Five min prior to palatable solution exposure, 
mice were injected IP with (a) saline or 0.1, 0.3, 1 and 3 mg/kg b. wt. of L-
368,899 (Tocris) at a dose range known to affect consummatory behavior (based 
on [3] and Chapter 2). The reference dose of the OTr antagonist was 1 mg/kg b. 
wt. (vs saline vehicle). The Bottles of palatable tastants were weighed before 
consumption and 1 hour after L-368,899 and saline administration. The amount 
of the palatable solution consumed was calculated and reported in g/kg of body 
weight. The amount of consumed palatable tastant was corrected for spillage. 
One-way ANOVA followed by Fisher’s post-hoc test was used to establish 
whether L-368,899 at different doses affected saccharin, sucrose, glucose and 
fructose consumption in the Cx36 Kos and compared to the WT values.  
4.2.2.4 OT neuronal activity feeding-related brain sites in response 
to a CTA in Cx36 KO mice. 
Mice were divided into four groups (n=8/group) and standard chow and water 
were removed from the cage before saline or LiCl (Sigma; 6 mEq/kg body wt; 
isotonic solution) injection in IP in Wt and Ko Cx36 mice. 60 minutes later, 
animals were anesthetized with urethane (35%) and perfused with 10 ml of 
saline followed by 50 ml of 4% paraformaldehyde (PFA) in 0.1 M phosphate 
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buffer (pH 7.4). Brains were excised and postfixed overnight in PFA at 4°C. 
Coronal 60-μm Vibratome (Leica) sections were processed for double (c-Fos and 
oxytocin) immunostaining. The tissue was treated for 10 min in 3% H2O2 in 10% 
methanol (in TBS, pH 7.4–7.6) and incubated overnight at 4°C in the goat anti-c-
Fos antibody (1:2000; Santa Cruz). Subsequently sections were incubated for 1h 
at room temperature in the rabbit-anti-goat antibody (Vector) and then in the 
avidin-biotin complex (1h; Vector). Peroxidase was visualized with 0.05% 
diaminobenzidine, 0.01 H2O2, and 0.2% nickel sulfate. All incubations were done 
in a mixture of 0.25% gelatin and 0.5% Triton X-100 (Sigma) in TBS. Intermediate 
rinsing was done with TBS. Following the completion of c-Fos staining, sections 
were further processed for visualization of OT. The procedure was similar to that 
used to staining for c-Fos. However, rabbit anti-oxytocin was used as the primary 
antibody (1:15000; Millipore, Temecula, CA), and nickel sulfate was omitted from 
the DAB solution to obtain brown staining. Sections were mounted on 
gelatinized slides, dried, dehydrated in ascending concentrations of ethanol, 
soaked in xylene, and embedded in Entellan. The number of Fos positive nuclear 
profiles in the regions of interest was counted on 4-5 sections per animal using 
Scion Image software. In the double staining analysis, the following estimates 
were assessed per section and then per region: the total number of OT neurons 
and the number of OT neurons positive for c-Fos. Cells were counted bilaterally, 
and the percentage of OT neurons containing c-Fos-positive nuclei was tabulated. 
An ANOVA and t-test was used to show the presence of significant difference 
between the number of c-Fos positive in oxytocin cells in saline and LiCl groups in 
WT and KO Cx36 mice. 
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4.2.3. Results 
The experiments show a relationship between the OT system and each aspect of 
food intake in the feeding-aberrant Cx36 KO model.  
The real-time PCR analysis in the feeding-for-energy paradigm revealed that Cx36 
KO mice maintained on an ad libitum chow availability schedule (and found to be 
consuming more chow-derived calories than WT controls) show a significantly 
lower level of OT expression in the Acb (p=0.03) and an increased OTr mRNA 
profile (p=3E-07) in the hypothalamus. There was no effect of genotype on OT 
expression in the hypothalamus (p=0.03) or on the OTr expression in the Acb 
(p=0.03) (Figure 4.2.1). 
In the feeding for reward experimental scenario, an OTr antagonist, L-368,899 (at 
the effective reference dose of 1 mg/kg b. wt. – as described in detail in Chapter 
2), administered just before the 2-h exposure to the palatable solutions, 
significantly increased intake of palatable sweet solutions (carbohydrates and 
non-carbohydrates) in WT animals. OTr antagonist-treated WTs drank 
significantly more sucrose (sal: 0.05±0.012; antagonist: 0.09±0.015; p=0.008), 
glucose (sal: 0.060.013±; antagonist: 0.08±0.017; p=0.02), fructose (sal: 
0.06±0.015; antagonist: 0.07±0.012; p=0.016). On the other hand, in the Cx36 KO 
mice, L-368,899 was ineffective in increasing appetite for palatable 
carbohydrates (sucrose: ANOVA F=1.5 p=0.15, glucose: ANOVA F=1 p= 0.74 and 
fructose: ANOVA F=1 p=0.1) and a sweet non-carbohydrate, saccharin (ANOVA 
F=0.6 p= 0.39) (Figure 4.2.2). 
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Finally, in the taste aversion paradigm, LiCl injection induced activation of OT 
neurons in the SON and PVN of both the Cx36 KO and WT strains (ANOVA F=31 
p= 0.009; PVN: (WT/saline vs Wt/LiCl p= 1E-15, Cx36 KO/saline vs Cx36KO/LiCl p= 
2E-10; SON: WT/saline vs Wt/LiCl p= 1E-10, Cx36 KO/saline vs Cx36 KO/LiCl p=2E-
15). Importantly, the Cx36-deficient animals that display hypersensitivity to 
aversive stimulation showed a heightened baseline (i.e., saline-induced) PVN OT 
neuronal activity (p=0.01) and significantly higher LiCl-induced OT neuronal 
activation in the SON (p=0.01) (Figure 4.2.3) 
 
 
. 
Figure 4.2.1: mRNA levels of OT and OTr in the hypothalamus and Acb of ad libitum 
chow-fed WT vs Cx36 KO mice. Differences in qPCR-established gene expression 
between groups were analyzed using a t-test.* - p<0.05; ***-p<0.001. 
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Figure 4.2.2: The effect of the OTr antagonist, L-368,899, at 0 (saline vehicle), 0.1, 0.3, 1 
and 3 mg kg/b. wt on the intake of solutions containing 0.1% saccharin (A), 10% sucrose 
(B),  10% glucose (C) and 10% fructose (D) in Cx36 KO mice.  The injections were 
performed just prior to 2-h tastant exposure period. Regular chow and water were 
removed from the cage and a single bottle containing one of the solutions was placed in 
the cage. 
Figure 4.2.3:  The percentage of Fos-positive OT cells in the paraventricular (PVN) and 
supraoptic (SON) nuclei in WT and Cx36 KO mice after an injection of saline or LiCl. OT 
neuronal activation was compared separately for the effect of saline injection and for 
the effect of LiCl injection (* - significant difference between WTs and KOs treated with 
the same injectant: p<0.05). 
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4.2.4. Discussion 
The Cx36 KO mouse is a unique genetic model that displays aberrant energy 
intake, reward-driven feeding and taste aversions. The complexity of food intake 
dysregulation in this knockout animal parallels the complexity of proposed 
involvement of OT in appetite control. Cx36-rich gap junctions have been found 
in feeding neural circuits [14, 16, 51], thus, in those brain pathways through 
which OT modifies appetite. Therefore, the presumed functional relationship 
between OT and Cx36 in feeding control would have to be based on an altered 
ability of OT to affect relevant aspects of food intake via the Cx36-deficient brain 
networks in the knockout mouse. In other words, an impairment in gap junction-
based integrity of feeding-related neural networks, would intuitively have to be 
reflected – endogenously - by an abnormal profile of the OT and OTr transcript 
levels and OT neuronal activity in response to feeding challenges, and – with 
exogenous neuroactive chemicals – by aberrant sensitivity (or lack thereof) to 
OTr ligands administered before feeding challenges.  
The current set of experiments provides data that support the hypothesis that 
endogenous responses of the OT/OTr system as well as behavioral 
responsiveness to OTr antagonist treatment are significantly affected in the 
animal whose brain circuits are devoid of Cx36. Importantly, this is evident in 
three key aspects of feeding control exerted by OT: energy-driven termination of 
food intake, feeding for pleasant taste and aversion-induced hypophagia [3, 36, 
52, 53]. 
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When Cx36 KO mice are maintained on freely accessible “bland” chow, thus, 
their ingestive behavior is driven mainly by calorie needs, they show abnormally 
high level of energy intake. There are obviously many possible factors that may 
underlie this overconsumption of energy in the KO model (e.g. higher energy 
expenditure or impaired absorptive processes), but even if the elevated feeding 
activity is caused by some other parameters, still satiation mechanisms have to 
be blunted in order to allow the animal to consume more food (despite, e.g., 
significant stomach distension or raised plasma osmolality). The real-time PCR 
experiment shows that ad libitum-fed Cx36 KO mice display a decreased level of 
OT mRNA in the Acb compared to their WT counterparts, which is in line with the 
general chow hyperphagia observed in the KO strain. Although it may seem 
somewhat surprising that hypothalamic OT expression is unaffected, one should 
note that our Chapter 3 studies on OT and Acb point to the fact that non-
hypothalamic OT also affects appetite for calories. Simultaneously, OTr mRNA 
levels in the hypothalamus are higher in the KOs, which indicates that OT 
signaling in the hypothalamus is imbalanced in the hyperphagic KO model.  
While the Cx36 KO mouse exhibited increased appetite for energy-dense “bland” 
chow, it also showed striking sensitivity to meal-associated toxicity. In the CTA 
paradigm (described in detail in Part 3.1 of this chapter), the KO mice acquired 
aversion even with very low doses of LiCl that did not cause a CTA in WT controls. 
OT is known to play a critical role in the process of development of aversive 
responses, both in producing an immediate termination of ingestive behavior 
once the toxin is detected by the brainstem chemoreceptors as well as in 
retrieval of aversion – once a potentially tainted ingestant is presented again [36, 
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53]. The immunohistochemical analysis of the OT system’s response provided 
herein sheds some light on the nature of the CTA phenomenon in Cx36 KOs. First, 
the percentage of PVN OT neurons is already higher in saline-treated (control) 
KO mice, which potentially underpins heightened sensitivity of these animals to 
even mild perturbations in internal milieu. Second, the SON OT neuronal 
activation is higher in the LiCl-injected Cx36 KOs than in similarly treated WTs, 
most likely contributing to a greater magnitude of an aversive response to the 
same dose of a given toxin (in this case, LiCl) of the knockout animals. 
Finally, the feeding reward paradigm, in which animals were given episodic 
access to palatable tastants provides evidence pertaining to atypical feeding 
responses to OTr antagonist administration in Cx36 KOs. It has been shown by 
our laboratory as well as by others ([3] and Chapters 2 and 3) that the OTr 
blocker, L-368,899, increases consumption of tasty carbohydrate and non-
carbohydrate (but sweet) solutions in mice and rats. The current set of studies 
employing a variety of highly preferred sweet tastants (containing saccharin or 
mono- or disaccharides) showed complete inability to enhance intake of these 
ingestants by blocking the OTr with the IP-injected BBB-penetrant OTr antagonist. 
Obviously, it should be emphasized that OT is clearly not the only peptide whose 
function within the Cx36-null feeding circuit is affected: Part 3.1 of this Chapter 
has identified opioids as another candidate group of molecules. In the network 
whose integrity is challenged by the absence of a key gap junction molecule, it is 
very much likely that some other feeding-related peptides are influenced in 
certain feeding scenarios as well. However, the fact that -in the Cx36 KO - the 
dysregulation of the OT system and of the three distinct aspects of appetite 
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controlled by OT go hand-in-hand, strongly suggests that the Cx36 molecule is a 
key component of feeding-related neural circuits through which OT executes its 
functions.  
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Chapter 5 
 
 
Discussion and Perspectives 
 
In the obesogenic environment, many individuals see their energy intake exceed 
energy expenditure and, in result, energy balance becomes dysregulated. In such 
environment, the usual reason to initiate and maintain consumption is not 
dictated by the necessity to replenish lacking calories, but rather it is driven by a 
pleasant taste of food. Therefore, identification of molecules and systems within 
the CNS that alter feeding for reward is an essential step in conceptualizing 
pharmacological treatment strategies that could assist in curbing excessive 
consumption of highly palatable foods.  
Upon undertaking the experimental work included in this thesis, it was clear that 
a neurohormone OT promotes termination of consumption in order to protect 
internal milieu (i.e., related mainly to energy needs, stomach distension and 
osmolality) [1-5]. At that time, some evidence had already been gathered 
pointing to a possible role of OT in reducing consumption of select palatable 
tastants [6-8]. For example, it had been shown that OT KO mice consume sweet 
carbohydrates and non-caloric saccharin less avidly than wild-type controls [9]. 
Pharmacological blockade of the OTr was known to elevate intake of sucrose 
over fat in sated mice [7], whereas OT administration reduced intake of glucose 
in food-deprived rats [6]. Opioid receptor antagonist injections that decrease 
palatable sucrose intake had been found to activate OT neurons [7], and OT gene 
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expression had been reported to increase after a high-sugar diet intake in rats [8]. 
Finally, long-term habitual consumption of sugar had been associated with 
diminished OT neuronal activity in response to a food load, suggesting that OT 
dysregulation leads to reward-driven overeating [10]. The studies included in this 
thesis as well as most recent reports by other authors (see the following 
publications as recent milestones in our understanding of the link between OT 
and feeding for palatability: [11, 12]) strongly suggest that OT serves as a cross-
link between mechanisms that bring on termination of consumption due to 
“homeostatic” and palatability-related (i.e., flavor- and macronutrient-specific) 
satiation. 
Prior to taking up this project and the most recent surge in interest in the 
functional relationship between OT and ingestive behavior, one of the greatest 
conundrums was associated with defining the role of OT in feeding for 
palatability. The data presented herein (as well as reports by others) 
demonstrate that OT is particularly effective in reducing intake of carbohydrates 
(regardless of whether sweet or non-sweet) as well as a non-carbohydrate 
sweetener, saccharin. Peripheral injections of the BBB-penetrant OT receptor 
antagonist, L-368,899 (Chapter 2), in mice led to an increase in the consumption 
of all the carbohydrates offered in that experiment. The wide range of 
carbohydrate-rich liquid diets included sweet sucrose (at several concentrations), 
fructose, glucose, and Polycose, as well as non-sweet cornstarch. Thus, L-368,899 
stimulated intake of all the carbohydrates independent of a subtype, sweetness 
and relative rewarding value of a molecule. It should be mentioned that the 
effective dose that was 10 times lower in sucrose tests than in trials involving the 
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remaining tastants. Saccharin solution intakes showed a strong trend towards an 
increase in L-368,899-treated mice, approaching significance (P=0.08). The latter 
was somewhat surprising considering the convincing data obtained by other 
authors in, e.g., OT knockout mice that overconsume saccharin [9, 13], strongly 
suggested the link between OT and appetite for this sweetener. It is possible that 
the episodic, mid-day schedule of saccharin presentation might have modified 
the response to saccharin in IP OT antagonist-injected mice, especially 
considering that the peripheral OT energy metabolism-related mechanisms come 
into play with an IP antagonist infusion [14, 15] and that saccharin was the only 
non-caloric palatable tastant offered, whereas sucrose, fructose, sucrose, and 
Polycose – albeit dilute – are the sources of energy. 
The notion that OT terminates consumption of carbohydrates and saccharin was 
strengthened by the outcome of Acb injection studies described in Chapter 3. 
Importantly, the data defined the AcbC, an integral part of the reward system, as 
a key site mediating the effects of OT on appetite.  In that set of experiments, 
AcbC OT decreased the intake of sucrose in energy non-deprived rats. 
Interestingly, when OT was injected directly in this reward-related site, very low 
doses of OT were effective in reducing appetite for non-caloric and highly 
palatable saccharin. Therefore, once the OT ligand-targeted receptor population 
is limited to the AcbC, the effectiveness of an OT receptor ligand to modify 
consumption of the non-caloric, palatable sweetener is greater. Notably, all 
anorexigenic effects of Acb OT were abolished by a pretreatment with an OTr 
antagonist, L-368,899, injected in the same site, which underscores the 
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involvement of the OT receptor in this process rather than of other non-selective 
peptide-receptor interactions.  
The link between OT acting in the reward system and the consumption of 
palatable tastants has also been suggested in studies utilizing intra-VTA 
administration of OT ligands. Mellis et al found that VTA-infused OT dose-
dependently promotes a decrease in sucrose consumption, whereas VTA acting 
OT receptor antagonists support enhanced appetite for sugar [12]. Furthermore, 
OT’s ability to modify intake for reward is abolished in the Cx36 KO strain (Part B 
of Chapter 4), in which reward processing is abnormal (Chapter 4, Part A). In this 
unique mouse model of aberrant Cx36 gap junction connectivity (mainly) within 
the reward and neuroendocrine systems of the CNS, OT receptor antagonist L-
368,899 fails to increase intake of sweet carbohydrate solutions (sucrose, 
fructose and glucose) and saccharin. It is therefore apparent that when the 
reward system’s functioning is impaired, OT ligands do not affect feeding for 
palatability. Thus, it is likely that the observed effects of OT on the intake of 
palatable tastants directly involve actual reward mechanisms. This is in concert 
with the fact that both OT and Cx36 have been found to affect other parallel 
aspects of reward, including alcohol abuse [16-26]. 
The changes in sensitivity to appetite modifying effects of OTr ligands are 
reflected by differences in the OT peptide and receptor mRNA content in the 
aforementioned key paradigms. In rats exposed to the saccharin solution 
(Chapter 3), OTr mRNA is downregulated in the AcbC. The hypothalamic OT 
mRNA levels in mice consuming diets enriched with carbohydrates or saccharin 
are particularly enhanced by carbohydrate intake (Chapter 2).  
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One should note, however, that the role of OT acting within the reward system is 
pleiotropic and it involves – among others - rewarding aspects of sociality (for 
example, see: [27-29]). Moreover, various aspects of social interactions (from the 
antagonistic nature of social exposure to bond formation), change OT tone in the 
CNS and the periphery (e.g., [30-34]). Thus, while studying effectiveness of OT 
receptor ligands in the control of feeding for reward, one should not neglect the 
fact that the type, frequency and quality of social behaviors may have a profound 
influence on the effectiveness of OT ligand treatment on appetite. As evidenced 
by the data presented in Chapter 3, AcbC OT did not change consummatory 
behavior in animals that were offered a rewarding meal in a social setting. This is 
in stark contrast with the results obtained in single-housed animals. However, 
this outcome is in agreement with the recently published data in the mouse 
model of sociality of feeding, in which it was shown that once a social 
environment of a palatable meal was introduced, only animals of a particular 
hierarchy status would express hyperphagia in response to the OTr antagonist IP 
treatment [35]. In that study, all animals – regardless of the hierarchy – displayed 
elevated appetite for sugar when a meal was given in a setting devoid of social 
cues.  
The results presented herein as well as by other authors [9,24,36-39] 
substantiate the claim that OT serves as a neuroregulator of carbohydrate-
specific satiety and inhibitor of consumption driven by sweet taste and that OT’s 
effects are – at least to some extent – mediated via the reward pathways; but 
these data also expand on our understanding of OT’s involvement in 
“homeostatic” meal control. The classical approach to defining the role of OT in 
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appetite has revolved almost entirely around homeostatic factors. Most notably, 
an increased level of OT neuronal activity and OT release have been measured at 
the end of a meal and in response to excessive plasma osmolality and stomach 
distension, as well as after ingestion of toxic foods whose consumption needs to 
be avoided in the future (CTA context) [3, 4]. In all these cases, the hypothalamic 
– brainstem pathways that encompass OT neurons and receptors have been 
typically identified as key neural mechanisms whose activation leads to 
termination of consummatory behavior [2,40,41]. Functional relationships 
between OT and other CNS peptides that affect consumption have also allow 
researchers to identify more precisely networks through which OT terminates 
consumption in order to maintain internal milieu. GLP-1 and alpha-MSH are two 
appetite suppressing neuropeptidergic systems whose direct input into the OT 
pathways has been described in most detail [42,43]. 
The current set of data provides additional evidence supporting the involvement 
of OT in the regulation of homeostatic aspects of feeding. OTr antagonist, L-
368,899, administered peripherally increased energy deprivation-induced intake 
of relatively “bland” carbohydrate, cornstarch in mice (Chapter 2). In the Cx36 KO 
model – which shows increased consumption of highly caloric bland chow in an 
ad libitum access setting (Chapter 4, Part A) – this propensity to overconsume 
energy was associated with a significantly higher baseline level of the 
hypothalamic OTr mRNA content and a lower OT mRNA in the Acb (Chapter 4, 
Part B). While it is clear that dysregulation of many other genes (aside from OT 
and – obviously considering the KO status – Cx36) may accompany this voracious 
eating phenotype, it is also critical that in the context of increased intake of 
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energy, OT system’s expression is changed, most likely being one of the factors 
facilitating this increased and sustained appetite for calories.  
It is extremely interesting that injections of OT in energy-deprived rats directly 
into the key site of the reward system, the AcbC, caused a marked decrease in 
the amount of standard laboratory chow eaten by the animals (Chapter 3). In 
fact, the results of AcbC OT injections mirror those obtained in VTA infusions of 
OT [12]. One explanation of this phenomenon is obviously that there is some 
element of palatability associated with the consumption of standard chow, 
hence changes in the reward system’s activity affect chow intake. However, one 
can propose also an alternative explanation, which – in any case – does not 
negate the aforementioned hypothesis, but rather enriches it. It is possible that 
OT acting in the AcbC and VTA serves as a component of molecular mechanisms 
that bridge intake for energy and intake for pleasure. While we typically envision 
pleasant taste as the main source of feeding reward, in the state of energy 
deprivation, the pleasure of consumption is derived largely from ingesting caloric 
food rather than from this food’s taste alone [44-46]. Hence, OT in the reward 
system may be reducing intake of energy (thus acting as a “homeostatic” satiety 
mediator) by diminishing reward stemming from consumption of calories (thus 
serving as an inhibitor of feeding reward). The fact that OT stimulation of the 
AcbC results in the activity of wider brain circuits that include hypothalamic OT 
neurons (multisynaptic pathways are most likely involved) suggests that OT-
derived signaling within the AcbC leads to further increases in hypothalamic OT 
neuronal activation, possibly ensuring that consummatory behavior does not 
continue. Finally, it should be mentioned that OT is not the only neuropeptide 
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that fits this description: also AcbC-infused GLP-1 affects both meal size and 
rewarding aspects of food consumption [47-49]. 
Overall, the findings presented in this thesis strongly suggest that OT acts as a 
cross-link molecule that bridges termination of consumption due to 
“homeostatic” and palatability-related (i.e., flavor- and macronutrient-specific) 
satiation. Aside from providing additional impetus on purely neurobiological and 
appetite-related basic research on OT, the complexity of OT’s role in ingestive 
behavior suggested here (and by other authors) might have a profound influence 
on whether OT-based pharmaceuticals can be successfully tried in obese patients.  
In the light of obesity “epidemic”, significant efforts have been made to 
introduce drugs that could alleviate at least some negative factors contributing 
to the development of excessive BMI; obviously, overeating is recognized as one 
of the most critical contributors. The general industry rules imposed by the US 
Federal Drug Administration on Developing Products for Weight Management 
[50] stipulate that medicinal products have to be scrutinized under very specific 
scenarios in order to reach the market. One of the key rules is that the anti-
obesity drug should be tested in patients with BMI > 30 kg/m2 or > 27 kg/m2 if co-
morbidities are present (sleep apnea; cardiovascular disease of diverse etiologies; 
type 2 diabetes; dyslipidemia; hypertension). The difference in mean weight loss 
between the drug and placebo groups should at least 5% (and statistically 
significant). The proportion of subjects who lose > 5% of body weight in the 
active- product group is at least 35%. The proportion of subjects who lose 
greater than or equal to 5% of baseline body weight in the active- product group 
is at least 35%, is approximately double the proportion in the placebo-treated 
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group.  Considering the many circumstances under which OT does not affect 
appetite, these guidelines might prove to be a very difficult obstacle for any OT-
based anti-obesity (anti-overeating) product. One of the major issues is that OT 
reduces intake of only some macronutrients and flavors: modern diet is 
extremely diverse and patients taking a drug that curbs overeating of only some 
foods might simply have their food preferences shifted by OT, and this shift will 
not be associated in any desirable weight loss. Furthermore, many people eat 
food in a social setting (e.g., with family members), hence the fact that OT’s 
effectiveness is reduced when a meal is offered in a social context, makes it a 
less likely candidate to successfully go through clinical trials. 
On the other hand, the fact that a neuropeptide affects only certain aspects of 
appetite makes it an attractive pharmaceutical whose role is aimed exclusively at 
overeating only specific tastants. Taking into account an anxiolytic effect of OT 
[51, 52], perhaps OT ligands could be used in those anxiety-prone or eating 
disorder patients whose overeating seems limited to sweet/high-carbohydrate 
diets. 
Finally, OT’s involvement in several unrelated behaviors suggests that this 
neuropeptide, may act as a behavioral “switch” between food intake and other 
competing behaviors/processes. OT might facilitate a choice between food 
intake and other behaviors/processes (e.g., social or sexual), in order to balance 
behaviors and contribute to the transient and long-term survival of the individual 
[35,53,54]. 
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Conclusions 
  
The overarching aim of the current thesis was to examine the hypothesis that OT 
suppresses appetite for sweet tastants by reducing palatability-driven reward. 
The findings of the studies are: 
 OT is involved in energy intake and this role is facilitated not only via 
circuits classically seen as “homeostatic”, but also via the nucleus 
accumbens, a reward-related site. 
 OT reduces appetite for carbohydrates; sucrose consumption appears to 
be particularly affected by OT. 
 OT tends to decrease appetite for non-carbohydrate and non-caloric 
sweetener, saccharin. 
  OT may serve as a key neuroregulator of carbohydrate-specific satiety 
and inhibitor of consumption driven by sweet taste. 
 OT acting via the AcbC (but not shell) decreases food intake driven by 
hunger and by reward. 
 Anorexigenic effects of AcbC OT do not stem from sickness/malaise. 
 A social environment in which a meal is presented reduces effectiveness 
of OT as an inhibitor of appetite. 
 OT in the AcbC affects activation of the AcbC itself as well as of 
hypothalamic sites involved in feeding control.  
 AcbC OTr mRNA levels change in response to both energy deprivation and 
exposure to palatable tastants.   
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 Cx36 is involved in the “homeostatic” and reward mechanisms governing 
appetite: (a) Cx36 deletion promotes overconsumption of highly caloric 
food; (b) Cx36 deletion promotes hypersensitivity to taste aversion; and 
(c) Cx36 deletion reduces feeding for reward. 
 Enhanced appetite for calorie-dense food in Cx36 knockouts is associated 
with changed expression of OT and OTr genes. 
 Cx36 knockouts’ increased sensitivity to taste aversion is associated with 
a higher number of activated OT neurons in toxin-treated animals. 
 Cx36 deletion impairs effectiveness of OTr blockade on consumption 
driven by sweet taste. 
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Abstract 
OBJECTIVES: Connexin 36 (Cx36) is a gap junction molecule ubiquitously expressed in the 
brain, especially in the reward circuit. Cx36 deletion is associated with dysregulation of 
GABA and dopamine in reward pathways and with decreased ethanol intake in Cx36 KO 
mice. Here, we used the Cx36 KOs to investigate whether the link between Cx36 and 
reward expands onto palatability-induced feeding. We determined intake of palatable 
tastants, expression profile of opioid system genes involved in feeding reward, and 
sensitivity of Cx36 KOs to feeding reward modifying opioid ligands, naltrexone and 
butorphanol. METHODS: Consumption of sweet (sucrose, glucose, fructose, saccharin) 
and lipid solutions during episodic (2h) and unrestricted access was measured in Cx36 
KO versus wild-type (WT) mice. WTs were treated with a pharmacological Cx36 blocker, 
quinine, to substantiate the findings. Opioid transcript levels were assessed with qPCR. 
Finally, naltrexone or butorphanol were administered in KOs and WTs prior to sucrose or 
saccharin solution presentation and dose-response curves were established. RESULTS: 
Cx36 KOs showed decreased consumption of all palatable solutions offered in a brief 
and unrestricted manner. Quinine in WTs decreased palatability-driven feeding. Cx36-
deficient mice maintained on a regular diet displayed an altered baseline expression 
profile of opioid system genes in the hypothalamus and nucleus accumbens. Cx36 KOs 
exhibited a diminished sensitivity to consumption modifying properties of naltrexone 
and butorphanol (sucrose) or a lack thereof (saccharin). CONCLUSIONS: Cx36 is essential 
in generating feeding for reward. The lack of Cx36 is associated with impaired 
functioning of the reward system, including its opioid-dependent component.  
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Highlights 
Cx36 knockout mice show diminished consumption of palatable tastants. 
Pharmacological blockade of Cx36 gap junctions decreases saccharin intake. 
Connexin 36 knockout mice display altered expression of opioid system genes. 
Connexin 36 knockouts show diminished feeding responses to opioid receptor ligands.  
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1. Introduction 
Gap junctions (GJs), pores formed by connexin (Cx) subunits, provide a means for 
intercellular communication in the brain [1]. The passage of molecules through neuronal 
GJs coordinates cell firing, and metabolic as well as transcriptional events between 
coupled neurons. Compared to chemical synapses, GJ electrical synapses synchronize 
outputs of coupled neurons and allow ultra-fast spread of information.  
Thus far, 20 connexin genes have been defined [2]. Among the two types of Cxs most 
ubiquitously expressed in mammalian neurons, only Cx36 is prevalent in the mature 
CNS [3]. Cx36 positive neurons have been demonstrated in the hippocampus, cerebral 
and piriform cortex, striatum, amygdala, cerebellum, mesencephalon, thalamus, 
hypothalamus, and various brain stem nuclei [3]. Cx36 has been shown to facilitate 
plasticity [4], promote glutamate-mediated cell death post-injury [5], affect motor 
learning [6, 7] mediate sensitivity to anesthetic drugs [8, 9], and affect learning- and 
anxiety-related parameters [10]. 
 
Comprehensive electrophysiological studies have established the role of Cx36 in the 
generation of high-frequency oscillations and synchrony [11], particularly within GABA 
and dopamine (DA) circuits [12][13][14][15]. The relationship between Cx36 and 
GABA/dopamine prompted studies on a possible link between Cx36 and reward. These 
experiments brought a groundbreaking discovery that Cx36 knockout (KO) mice are less 
prone to drinking alcohol. The loss of Cx36-dependent electrical coupling within the key 
reward pathway component, the ventral tegmental area (VTA), leads to the 
dyssynchrony of the GABA system resulting in disinhibition of DA neurons (hyper-DA 
state), and consequently decreases the hedonic value of ethanol intake [15].  
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In the current set of studies, we used the Cx36 KO mouse model to investigate whether 
the link between Cx36 and reward expands onto the pleasure of consumption of 
palatable tastants. First, we measured consumption of sweet and lipid solutions in 
episodic and unrestricted access paradigms in Cx36 KO versus WT mice and 
substantiated our findings by using a pharmacological blocker of Cx36 gap junctions, 
quinine, in WT animals. As the consumption of palatable tastants was lower in the KO 
animals, we hypothesized that the genetic deletion of Cx36 affects baseline expression 
of opioid system-related genes, which are the key components of central mechanisms 
governing feeding for pleasure [16] thereby diminishing KO animals’ sensitivity to 
feeding reward. Hence opioid transcript levels were assessed with real-time PCR in the 
hypothalamus and nucleus accumbens of Cx36 KOs and their background strain. Finally, 
we tested sensitivity of Cx36 KOs versus WTs to feeding inhibitory properties of an 
opioid receptor antagonist, naltrexone, and feeding stimulatory properties of an agonist, 
butorphanol, on sugar and saccharin solution intake. 
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2. Materials and Methods 
2.1. Animals 
The Cx36 KO model, developed and kindly provided to our laboratories by Prof. David 
Paul [17], has been used by us and others in earlier studies [18], [19]. Male homozygous 
Cx36 KO and WT littermates (C57/B6-129SvEv mixed background) were individually 
housed in conventional cages with a 12:12 LD photoperiod (lights on at 0700) in a 
temperature-controlled room (21°C). Age-matched animals weighed ca. 26 g ± 3 at the 
beginning of the studies (there was no difference in b. wt. between the 
genotypes). Mice had unlimited access to tap water and standard rodent chow (Teklad 
Global Diet 2018) throughout the studies unless noted otherwise. The procedures 
described herein were approved by the University of Waikato animal ethics committee. 
2.2. Ingestive behavior assessment 
Prior to the beginning of exposing animals to non-standard tastants, we determined that 
despite the same body weight as WT counterparts, age-matched Cx36 KO mice eat more 
regular chow over a 24-h period with water and food available ad libitum (KOs: 
0.18±0.003 g/kg b. wt; WTs: 0.11±0.01; p=0.01 in t-test), which suggests energy 
metabolism changes in the KO strain. 
2.2.1. Episodic intake of palatable tastant solutions in Cx36 KO vs WT mice 
In a series of experiments, we tested the intake of 0.1% saccharin, 5% sucrose, 5% 
glucose, 5% fructose or 4.1% Intralipid (Fresenius, Sweden) solutions in a single-bottle 
no-choice paradigm. Cx36 KO and WT mice (n=13-18/tastant) had been pre-exposed to 
the respective solutions 2 h/day (10:00–12:00) for 5 days. Chow and water were 
removed from the cages for the 2-h period of palatable tastant presentation. The 
animals were then given a single bottle containing a palatable tastant. The amount of 
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the solution consumed was calculated and the means were reported in g/kg of b. wt. A 
Student’s t-test was used to assess differences in consumption for each of the palatable 
solutions between WT and KO animals (significant when p≤0.05). 
As a control study for the ability of Cx36 gap junctions to affect episodic consumption of 
palatable tastants, we subjected the WT mice to a similar paradigm of saccharin solution 
availability as described above, injected them with saline or 30 mg/kg b. wt quinine 
(Cx36 gap junction blocker) 5 minutes before palatable tastant presentation and 
determined saccharin solution intake in the 2-h test period. The dose of quinine was 
selected based on previous studies showing antinociceptive and antiepileptic effects of 
the compound [20], [21]. The amount of consumed saccharin solution was expressed in 
g/kg b. wt. and the data of saline vs. quinine groups compared with a t-test (significant 
when p≤0.05). 
2.2.2. Unrestricted intake of palatable solutions in Cx36vKO vs WT mice 
We assessed the intake of 0.1% saccharin, 5% sucrose, 5% glucose, 5% fructose or 4.1% 
Intralipid when each of these tastants was available ad libitum (along with standard 
chow and water) for 3 consecutive days. KO and WT mice were given a single bottle 
containing a palatable tastant for 3 days (n=8/WT and n=8 KO for each tastant). The 
amount of the tastants and chow consumed on Day 2 and 3 (data from Day 1 were not 
included in the analysis to discount the potential effect of novelty) was calculated and 
the means were reported in g/kg of b. wt. A Student’s t-test was used to establish the 
difference between WT and Cx36 KO consumption in consumption (significant when 
p≤0.05). 
2.3. Baseline expression of opioid system genes in the hypothalamus and nucleus 
accumbens in Cx36 KO vs. WT mice 
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Wt and Cx36 KO mice (n=8/group), maintained on ad libitum access to standard chow 
and water, were decapitated (10:00-11:00) and the hypothalamus and nucleus 
accumbens were collected according to the Paxinos and Watson brain atlas. The 
tissue was placed in RNAlater at room temperature for 2h and then stored at -80°C. RNA 
was extracted by the Quick-RNATMkits (Zymo Research) and the absence of DNA was 
confirmed by PCR. Total RNA concentration was measured with Nanodrop 2000 
(Thermo Scientific). For cDNA synthesis, 9 μl of RNA was reverse-transcribed in a final 
volume of 20 μl containing 10 μl 2X RT Reaction Solution and 1 μl Enzyme Mix 
(HiSenScriptTM RH(-) cDNA Synthesis Kit, iNtRON Biotechnology). The reaction was 
performed for 1h at 42°C, followed by 5 min at 85°C and 5 min at 4°C, and the presence 
of cDNA was confirmed by PCR. Each rtPCR, with a total volume of 20 μl, contained 8 μl 
template cDNA, 2μl Primers Mix (Forward and Reverse primers) and 10 μl of 2X 
RealMODTM GH Green Real-time PCR Master Mix (Master Mix Kit, iNtRON). rtPCRs were 
done in duplicates, and negative controls were included on each plate. Amplification 
was performed as follows: denaturation at 94°C for 5 min, 50 cycles of denaturation at 
94°C for 10 s, annealing for 15 s, and extension at 62°C for 30 s.  Three housekeeping 
genes were analyzed (Table 1). A Rotor-Gene SYBR Green PCR (QIAGEN) was used. Data 
analyses have been performed by Rotor-Gene 6000 software 1.7 (QIAGEN). Primer 
efficiencies of 11 genes (Table 1) were calculated and samples were corrected for 
differences in efficiencies. The Pfaffl equation [22] [23] was used to calculate 
normalization factors based on housekeeping gene expression. Differences in gene 
expression between groups were analyzed using a t-test (different when p≤0.05). 
2.5. Effect of opioid receptor agonist and antagonist on consumption of sweet 
palatable tastants in Cx36 KO vs. WT mice 
Several days prior to the beginning of the experiments, Cx36 KO and WT mice had been 
pre-exposed to 0.1% saccharin or 10% sucrose solutions for 24 h to prevent 
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neophobia. Similar to the episodic exposure experiments described above (section 2.2.1), 
animals (n=7-10/group) were accustomed to having access to either 0.1% saccharin or 
10% sucrose for 2 h/day (1000–1200 h). Standard food and water were removed for the 
2-h period of palatable tastant presentation. Five min prior to palatable solution 
exposure, mice were injected IP with (a) saline or 0.03,0.1, 0.3, 1 and 3 mg/kg b. wt. of 
naltrexone or (b) saline or 0.1, 0.3, 1 and 3 mg/kg b. wt. of butorphanol tartrate. The 
amount of the palatable tastant consumed during the 2-h period was calculated in g/kg 
of b. wt. One-way ANOVA followed by Fisher’s post-hoc test was used to establish 
effective doses of naltrexone and butorphanol in saccharin and sucrose consumption for 
the Cx36 KO and WT strains (different when p≤0.05).  
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3. Results 
Mice lacking the functional Cx36 gene display diminished intake of palatable tastants in 
both episodic and unrestricted access paradigms. The KO animals drank significantly less 
of the sweet palatable solutions and lipid emulsion (saccharin: p=0.008,; sucrose, 
p=0.009; glucose, p=1E-5; fructose, p=0.0003, Intralipid, p=0.002) offered in a brief 2-h 
session (with no chow or water available during that time; Fig.1A). A similarly diminished 
intake of the palatable tastants was observed when saccharin (p=0.02) sucrose (p=2E-6), 
glucose (p=2E-6), fructose (p=2E-7) and Intralipid (p=0.0002) were given in an 
unrestricted manner for 48 h (chow/water available ad libitum; Fig.1B). Importantly, 
water intake did not differ between KO and WT mice (p=0.23).  
Cx36 blocker, quinine, administrated IP just before the 1-h exposure to the saccharin 
solution in WT mice, significantly decreased the intake of this sweet tastant (p=0.004; 
Fig. 1C). 
In the PCR studies, we found that baseline expression of opioid system genes differs in 
Cx36KO vs WT mice maintained on a standard diet (Fig.2). The KOs showed decreased 
mRNA levels of KOR (p=1E-06), MOR (p=5E-08), PNOC (p=0.0005), ORPL1 (p=6E-05), and 
increased DYN mRNA content (p=1E-05) in the hypothalamus, whereas PENK transcript 
expression was higher (p=0.03) in the nucleus accumbens.  
NTX or butorphanol injections in animals given access to saccharin or sucrose, produced 
diiferent dose-response profiles in Cx36 vs WT  mice (Fig 3). While the 0.1-mg and 0.3-
mg doses of NTX decreased sucrose consumption in WTs (p=0.02 and p=0.01, 
respectively), 3 mg NTX had to be used to generate a reduction in sucrose intake in KOs 
(p=0.007). NTX at 1 mg (p=0.008) decreased saccharin intake in WT animals, but even 
the 3-mg dose was ineffective in the KO strain.  
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Conversely, butorphanol increased sucrose consumption at 0.3 mg (p=0.02; and 1 mg 
(p=0.004) in WTs, whereas 3 mg (p=0.01) was the lowest effective dose in KOs (Fig. 3C). 
Saccharin consumption increased after injection of 0.3 and 1 mg butorphanol in WT 
mice (p=0.004 and p=0.004, respectively) but it remained unchanged even after the 3-
mg butorphanol treatment (Fig. 3).  
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4. Discussion 
Excessive intake of highly palatable tastants brings on most profound metabolic and 
energy balance consequences for the organism [24]. The mesolimbic reward pathways 
as well as reward-related molecules scattered throughout the widespread network of 
sites that govern food intake and energy metabolism, promote overconsumption of 
tasty foods [25, 26]. Cx36, as a key molecular component of gap junctions in the adult 
CNS, serves a critical role in ensuring functional integrity of brain circuits, including those 
involved in reward [3, 15]. It has been previously shown that silencing Cx36 expression 
leads to a disruption of GABA and DA signaling [12-15]. Genetic deletion of Cx36 has also 
been found to decrease ethanol consumption in mice [15]. The current set of data 
shows for the first time that Cx36 gene knockout and the pharmacological blockade of 
Cx36 GJs diminish intake of palatable solutions in mice, and that dysregulation of the 
opioid system - a consequence of impaired Cx36 GJ coupling - likely underlies this 
reduced drive to eat for pleasure. 
Animals typically prefer sweet and fatty foods, and they ingest large quantities of solid 
and liquid diets that contain sugars, non-carbohydrate sweeteners, and/or fats, 
regardless of overall caloric density of such diets [27, 28]. Importantly, reward-driven 
consumption of solid and liquid diets occurs regardless of the fact whether the animal 
has or has not been food- or water-deprived [29, 30]. Non-deprived Cx36 KO mice did 
consume the palatable liquid diets given episodically and in an unrestricted manner, 
which suggests that these solutions are not completely devoid of hedonic value to these 
animals. However, each of the palatable tastants was consumed less avidly by the KOs 
compared to their WT counterparts, indicating that the processing of rewarding aspects 
of consumption of these liquid diets was impaired in the Cx36-deficient mice. That water 
intake does not differ between KOs and WTs makes it unlikely that the effect was cause 
by differences in thirst responsiveness. The fact that KOs ingest less of the non-caloric 
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saccharin solution than WT controls rules out a scenario in which diminished energy 
needs are the culprit underlying lower intake of palatable tastants. It should also be 
noted that the feeding reward experiments presented herein employed a wide variety 
of tastants that engage different subsets of taste receptors; therefore, along with the 
previously reported data on the relationship between Cx36 and alcohol-derived reward 
[15], our results imply that aberrant processing of reward in Cx36 deficiency expands 
upon pleasure-derived consummatory behavior.  
Interestingly, administration of quinine in non-deprived WT mice just prior to their 
gaining brief episodic access to the saccharin solution generated a decrease in saccharin 
intake. The parallel effects of gene deletion and pharmacological blockade of the GJ 
molecule lend us more confidence in defining Cx36 as being involved in feeding reward. 
Overall, changes in reward processing are evoked not just by a constitutive absence of 
the Cx36 gene, but also by using a transient Cx36 blocker; hence they can be dependent 
on acute changes in the Cx36 GJ functional status as well as on long-term molecular 
changes associated with the the lack of Cx36. 
It has been previously reported that Cx36 deficiency in the KO model leads to significant 
abnormalities in DA and GABA signaling within the VTA-accumbens pathways, thereby 
contributing to the impaired processing of rewarding stimulation [12-15]. Our real-time 
PCR data suggest that changes in the molecular content of reward-related circuits are 
even more profound as the baseline expression profile of genes that give rise to select 
opioid peptides and receptors is greatly affected. The key role of endogenous opioids in 
palatability-induced consumption has been shown beyond reasonable doubt. It is well 
known that opioid receptor agonists induce intake of preferred tastants, while 
antagonists are effective in decreasing intake of tasty foods [31][32]. Modifications in 
access to palatable diets affect opioid peptide/receptor mRNA and protein levels [33-35], 
whereas constitutive and conditional changes in expression of opioid system genes are 
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associated with an altered drive to ingest rewarding tastants [36-38]. That Cx36 KO 
animals maintained on standard “bland” chow show different levels of opioid mRNAs 
indicates that - already at the baseline behavioral state - there is an atypical expression 
of genes related to feeding reward, most likely being one of the underlying factors in 
aberrant processing of palatability in Cx36 KOs. It should be noted that opioid system 
mRNA levels were changed not only in the nucleus accumbens, which is intuitive taking 
into account its role in reward, but predominantly in the hypothalamus, where the 
receptor transcripts were greatly affected. While numerous intraparenchymal injection 
studies have shown that opioid receptors in the hypothalamus modify palatability-
driven feeding [39], they are also though to couple reward system’s activity with the 
homeostatic and neuroendocrine responses of the hypothalamus [31, 40] . 
The real-time PCR findings showing an altered expression profile of opioid-related genes 
are further substantiated by the studies utilizing injections of opioid receptor ligands 
that are known to stimulate (butorphanol) or reduce (naltrexone) consumption of 
palatable tastants [31][32]. We found that WT mice offered either sucrose or saccharin 
exhibited a typical orexigenic response to butorphanol and hypophagia after naltrexone 
treatment. On the other hand, Cx36 KOs exhibited a diminished sensitivity to 
consumption modifying properties of each of the opioid ligands (sucrose) or a lack 
thereof (saccharin). While it is difficult to speculate whether the marked shifts in the 
dose-response curves can be directly attributed to changes in opioid system’s expression 
profile or rather to impaired coupling of reward signaling due to DA and GABA 
disruption (or both), it is clear that Cx36 deletion leads to gross abnormalities in the 
molecular content, sensitivity and functioning of reward circuits.  
In sum, we conclude that Cx36 is essential in generating avid consumption of palatable 
tastants. The lack of Cx36 is associated with impaired functioning of the reward system, 
including its opioid-dependent component. 
228 
 
5. Acknowledgments 
This research was supported by the Waikato Research Trust Fund and the Royal Society 
of New Zealand Marsden grant. The authors wish to thank Ms. Sarah Gwynn for help 
with animal husbandry. 
  
229 
 
References 
 
1. Spray, D.C. and M.V. Bennett, Physiology and pharmacology of gap junctions. 
Annu Rev Physiol, 1985. 47: p. 281-303. 
2. Bosco, D., J.A. Haefliger, and P. Meda, Connexins: key mediators of endocrine 
function. Physiol Rev, 2011. 91(4): p. 1393-445. 
3. Rash, J.E., et al., Immunogold evidence that neuronal gap junctions in adult rat 
brain and spinal cord contain connexin-36 but not connexin-32 or connexin-43. 
Proc Natl Acad Sci U S A, 2000. 97(13): p. 7573-8. 
4. Postma, F., et al., Electrical synapses formed by connexin36 regulate inhibition- 
and experience-dependent plasticity. Proc Natl Acad Sci U S A, 2011. 108(33): p. 
13770-5. 
5. Fontes, J.D., et al., Death of Neurons following Injury Requires Conductive 
Neuronal Gap Junction Channels but Not a Specific Connexin. PLoS One, 2015. 
10(5): p. e0125395. 
6. Van Der Giessen, R.S., et al., Role of olivary electrical coupling in cerebellar 
motor learning. Neuron, 2008. 58(4): p. 599-612. 
7. van Essen, T.A., et al., Anti-malaria drug mefloquine induces motor learning 
deficits in humans. Front Neurosci, 2010. 4: p. 191. 
8. Voss, L.J., et al., Role of Cx36 gap junction modulation in general anaesthetic 
anticonvulsant action. Eur J Pharmacol, 2010. 643(1): p. 58-62. 
9. Jacobson, G.M., et al., The role of connexin36 gap junctions in modulating the 
hypnotic effects of isoflurane and propofol in mice. Anaesthesia, 2011. 66(5): p. 
361-7. 
10. Schoenfeld, T.J., et al., Gap junctions in the ventral hippocampal-medial 
prefrontal pathway are involved in anxiety regulation. J Neurosci, 2014. 34(47): 
p. 15679-88. 
11. Posluszny, A., The contribution of electrical synapses to field potential 
oscillations in the hippocampal formation. Front Neural Circuits, 2014. 8: p. 32. 
12. Allison, D.W., et al., Connexin-36 gap junctions mediate electrical coupling 
between ventral tegmental area GABA neurons. Synapse, 2006. 60(1): p. 20-31. 
13. Lassen, M.B., et al., Brain stimulation reward is integrated by a network of 
electrically coupled GABA neurons. Brain Res, 2007. 1156: p. 46-58. 
14. Moore, H. and A.A. Grace, A role for electrotonic coupling in the striatum in the 
expression of dopamine receptor-mediated stereotypies. 
Neuropsychopharmacology, 2002. 27(6): p. 980-92. 
230 
 
15. Greenstone, M., et al., Upper airway manifestations of primary ciliary 
dyskinesia. J Laryngol Otol, 1985. 99(10): p. 985-91. 
16. Olszewski, P.K., et al., Opioids as facilitators of feeding: can any food be 
rewarding? Physiol Behav, 2011. 104(1): p. 105-10. 
17. Deans, M.R., et al., Synchronous activity of inhibitory networks in neocortex 
requires electrical synapses containing connexin36. Neuron, 2001. 31(3): p. 
477-85. 
18. Jacobson, G.M., et al., Connexin36 knockout mice display increased sensitivity 
to pentylenetetrazol-induced seizure-like behaviors. Brain Res, 2010. 1360: p. 
198-204. 
19. Steffensen, S.C., et al., The role of connexin-36 gap junctions in alcohol 
intoxication and consumption. Synapse, 2011. 65(8): p. 695-707. 
20. Nassiri-Asl, M., F. Zamansoltani, and B. Torabinejad, Antiepileptic effects of 
quinine in the pentylenetetrazole model of seizure. Seizure, 2009. 18(2): p. 129-
32. 
21. Nassiri-Asl, M., F. Zamansoltani, and A.A. Zangivand, The inhibitory effect of 
trimethylamine on the anticonvulsant activities of quinine in the 
pentylenetetrazole model in rats. Prog Neuropsychopharmacol Biol Psychiatry, 
2008. 32(6): p. 1496-500. 
22. Pfaffl, M.W., A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res, 2001. 29(9): p. e45. 
23. Lyle, W.H., Letter: D-penicillamine and haemolytic anaemia. Lancet, 1976. 
1(7956): p. 428. 
24. O'Rahilly, S. and I.S. Farooqi, Human obesity: a heritable neurobehavioral 
disorder that is highly sensitive to environmental conditions. Diabetes, 2008. 
57(11): p. 2905-10. 
25. Volkow, N.D., G.J. Wang, and R.D. Baler, Reward, dopamine and the control of 
food intake: implications for obesity. Trends Cogn Sci, 2011. 15(1): p. 37-46. 
26. Egecioglu, E., et al., Hedonic and incentive signals for body weight control. Rev 
Endocr Metab Disord, 2011. 12(3): p. 141-51. 
27. Levin, B.E., et al., Selective breeding for diet-induced obesity and resistance in 
Sprague-Dawley rats. Am J Physiol, 1997. 273(2 Pt 2): p. R725-30. 
28. Pickering, C., et al., Withdrawal from free-choice high-fat high-sugar diet 
induces craving only in obesity-prone animals. Psychopharmacology (Berl), 
2009. 204(3): p. 431-43. 
231 
 
29. Berner, L.A., N.M. Avena, and B.G. Hoebel, Bingeing, self-restriction, and 
increased body weight in rats with limited access to a sweet-fat diet. Obesity 
(Silver Spring), 2008. 16(9): p. 1998-2002. 
30. Olszewski, P.K., et al., Oxytocin receptor blockade reduces acquisition but not 
retrieval of taste aversion and blunts responsiveness of amygdala neurons to 
an aversive stimulus. Peptides, 2013. 50: p. 36-41. 
31. Olszewski, P.K., et al., Opioids affect acquisition of LiCl-induced conditioned 
taste aversion: involvement of OT and VP systems. Am J Physiol Regul Integr 
Comp Physiol, 2000. 279(4): p. R1504-11. 
32. Yeomans, M.R. and R.W. Gray, Effects of naltrexone on food intake and 
changes in subjective appetite during eating: evidence for opioid involvement 
in the appetizer effect. Physiol Behav, 1997. 62(1): p. 15-21. 
33. Welch, C.C., et al., Palatability-induced hyperphagia increases hypothalamic 
Dynorphin peptide and mRNA levels. Brain Res, 1996. 721(1-2): p. 126-31. 
34. Spangler, R., et al., Opiate-like effects of sugar on gene expression in reward 
areas of the rat brain. Brain Res Mol Brain Res, 2004. 124(2): p. 134-42. 
35. Gosnell, B.A. and A.S. Levine, Reward systems and food intake: role of opioids. 
Int J Obes (Lond), 2009. 33 Suppl 2: p. S54-8. 
36. Papaleo, F., et al., Decreased motivation to eat in mu-opioid receptor-deficient 
mice. Eur J Neurosci, 2007. 25(11): p. 3398-405. 
37. Kovacs, K.M., et al., Decreased oral self-administration of alcohol in kappa-
opioid receptor knock-out mice. Alcohol Clin Exp Res, 2005. 29(5): p. 730-8. 
38. Tabarin, A., et al., Resistance to diet-induced obesity in mu-opioid receptor-
deficient mice: evidence for a "thrifty gene". Diabetes, 2005. 54(12): p. 3510-6. 
39. Glass, M.J., C.J. Billington, and A.S. Levine, Opioids and food intake: distributed 
functional neural pathways? Neuropeptides, 1999. 33(5): p. 360-8. 
40. Olszewski, P.K. and A.S. Levine, Central opioids and consumption of sweet 
tastants: when reward outweighs homeostasis. Physiol Behav, 2007. 91(5): p. 
506-12. 
 
  
232 
 
Table 1. Forward and reverse real-time PCR primer sequences. 
 
  
Opioid system genes     
 Forward Reverse 
KOR CAC CTT GCT GAT CCC AAA TTC CCA AGT CAC CGT CAG 
MOR CCT GCC GCT CTT CTC TGG  CGG ACT CGG TAG GCT GTA AC 
PNOC AGC ACC TGA AGA GAA TGC CG CAT CTC GCA CTT GCA CCA AG 
DYN GAC AGG AGA GGA AGC AGA AGC AGC ACA CAA GTC ACC 
ORPL1 ATG ACT AGG CGT GGA CCT GC GAT GGG CTC TGT GGA CTG ACA 
PENK CGA CAT CAA TTT CCT GGC GT AGA TCC TTG CAG GTC TCC CA 
Housekeeping genes 
B actin TGG CAC CAC ACC TTC TAC AAT GAG GGG TCA TCT TTT CAC GGT TGG 
Atp5b GGC ACA ATG CAG GAA AGG TCA GCA GGC ACA TAG ATA GCC 
B tub CGG AAG GAG GCG GAG AGC AGG GTG CCC ATG CCA GAG C 
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Figure legends 
Fig. 1. Connexin 36 knockout (Cx36 KO) mice consume smaller amounts of palatable 
solutions offered (A) episodically for 2 h or (B) in an unrestricted 48-h access paradigm, 
compared to wild-type (WT) controls. A peripheral injection of a pharmacological 
blocker of Cx36 gap junctions, quinine, reduces saccharin solution intake (C). * - p≤0.05; 
** - p≤0.01; *** - p≤0.001. 
Fig. 2. Connexin 36 knockout (Cx36 KO) mice having unrestricted access to standard 
food and water display a different baseline mRNA expression profile of select opioid 
system genes than wild-type (WT) controls. Gene expression levels in the hypothalamus 
and nucleus accumbens were measured with real-time PCR. KOR, kappa opioid receptor; 
MOR, mu opioid receptor; PNOC, pronociceptin; ORPL1, nociceptin/orphanin FQ 
receptor; PENK, proenkephalin; POMC, proopiomelanocortin. * - p≤0.05; ** - p≤0.01; 
*** - p≤0.001. 
Fig. 3. Effects of naltrexone (top: A, B) and butorphanol tartrate (bottom: C, D) on the 
intake of sucrose (A,C) and saccharin (B, D) solutions offered for 2 h to connexin 36 
knockout (Cx36 KO) and wild-type (WT) mice. Doses of naltrexone and butorphanol 
represent mg/kg b. wt. injected intraperitoneally. * - p≤0.05; ** - p≤0.01; *** - p≤0.001. 
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